Glycosylated Prodrugs
Glycosylated prodrugs targeting glucosylceramidase beta 2 (GBA2) convert to active compounds at inflammation or cancer sites, addressing the side effect issue of corticosteroids by providing localized therapy with reduced systemic impact.
Patent Information
- Application Number
- JP2024525969
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-02
- Filing Date
- 2022-11-02
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing corticosteroids, such as glucocorticoids, have significant side effects due to their broad immunosuppressive activity mediated through the glucocorticoid receptor (GR), which affects both therapeutic and side effects, limiting their clinical use.
Development of glycosylated prodrugs that are substrates for glucosylceramidase beta 2 (GBA2), allowing targeted conversion to active compounds at sites of inflammation or cancer, reducing off-target effects by limiting activity until cleaved by GBA2.
The glycosylated prodrugs provide localized therapeutic activity with reduced systemic side effects, enhancing efficacy in treating inflammation and cancer while minimizing adverse reactions.
Smart Images

Figure 2024542060000020 
Figure 2024542060000021 
Figure 2024542060000022
Abstract
Description
[Technical field]
[0001] The present invention relates to compounds comprising a monosaccharide or disaccharide and a therapeutic moiety (e.g., an anti-inflammatory or chemotherapeutic moiety) and pharmaceutically acceptable salts, stereoisomers, acids or solvates thereof. The compounds can be substrates for glucosylceramidase beta 2 (GBA2), and are thus prodrugs that provide active compounds after cleavage of the monosaccharide or disaccharide by GBA2. Also provided are pharmaceutical compositions comprising the compounds, and various medical and non-medical uses of the compounds and compositions.
[0002] Corticosteroids, such as glucocorticoids, are a class of compounds commonly used clinically for their immunosuppressive effects, such as prednisolone and dexamethasone (Burns, 2016, The History of Cortisone Discovery and Development. Rheum Dis Clin North Am 42, 1-14, vii). They are used to treat a wide range of inflammatory and immune disorders, such as asthma, rheumatoid arthritis, inflammatory bowel disease and psoriasis, hematological tumors such as leukemia, and to reduce inflammatory complications of infectious diseases, such as tuberculosis and COVID-19 (Barnes, 2017, Glucocorticosteroids. Handb Exp Pharmacol 237, 93-115; Buttgereit, 2020, Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat Rev Rheumatol 16, 239-246; Rhen and Cidlowski, 2005, Antiinflammatory action of glucocorticoids-- new mechanisms for old drugs. N Engl J Med 353, 1711-1723).Although they are highly effective in dampening inflammatory and other immune responses, their clinical use is limited by the severity of side effects, including increased risk of diabetes, disruption of the endocrine system, osteoporosis, delayed and disrupted wound healing, and inhibition of growth and fertility (Hoes et al., 2009, Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 68, 1833-1838; McDonough et al., 2008, The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 20, 131-137; Schacke et al., 2002, Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101, 227-232).
[0003] All effects of glucocorticoids are mediated by an intracellular receptor, the glucocorticoid receptor (GR), which is expressed in almost every cell in our body (Nicolaides et al., 2010). Upon activation by ligand, the cytoplasmic GR is activated and translocates to the nucleus, where it acts as a transcription factor and regulates the transcription of a wide variety of target genes. GR regulates gene expression in several ways (Meijsing, 2015, Mechanisms of Glucocorticoid-Regulated Gene Transcription. Adv Exp Med Biol 872, 59-81; Miranda et al., 2013, Complex genomic interactions in the dynamic regulation of transcription by the glucocorticoid receptor. Mol Cell Endocrinol 380, 16-24; Ramamoorthy and Cidlowski, 2016, Corticosteroids: Mechanisms of Action in Health and Disease. Rheum Dis Clin North Am 42, 15-31, vii; Ratman et al., 2013, Beck, IM, and De Bosscher, K. (2013). How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol Cell Endocrinol 380, 41-54). It can bind as a dimer (although recently binding as a tetramer has also been reported) to specific sequences in the genome, the so-called glucocorticoid responsive elements (GREs), and promote or repress gene transcription by recruiting specific transcriptional coregulator proteins that modulate the local chromatin structure and subsequently recruit and activate the transcriptional machinery.This process is generally referred to as transactivation, but binding to a certain class of GREs (so-called negative GREs) results in transcriptional repression. Alternatively, GR can regulate gene transcription through reciprocal effects with other transcription factors without dimerizing. For example, it can physically interact with the p65 subunit of the NF-κB transcription factor complex and thus inhibit the activity of this transcription factor. Interaction of GR with other transcription factors can also enhance transcriptional activity, but this process is generally referred to as transrepression.
[0004] Initially, this transrepression activity of GR was thought to be the main mechanism underlying the anti-inflammatory action of glucocorticoids, whereas most of the side effects of glucocorticoids were thought to be due to the transactivation activity of GR (Schacke et al., 2002, Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96, 23-43; Schacke et al., 2004, Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101, 227-232). Therefore, to improve the therapeutic rate of glucocorticoid drugs, much effort has been devoted to the development of novel GR agonists that induce the transrepression activity of GR rather than the transactivation activity (Sundahl et al., 2015, Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds. Pharmacol Ther 152, 28-41). However, although some promising compounds have been developed (e.g., Baiula et al., 2014, Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy. Drug Des Devel Ther 8, 745-757; Biggadike et al., 2007, Nonsteroidal glucocorticoid agonists: tetrahydronaphthalenes with alternative steroidal A-ring mimetics possessing dissociated (transrepression / transactivation) efficacy selectivity. J Med Chem 50, 6519-6534; Dewint et al., 2008, A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 180, 2608-2615; Stock et al., 2017, Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study. Int J Rheum Dis 20, 960-970; Zhang et al., 2020, Natural and synthetic compounds as dissociated agonists of glucocorticoid receptor. Pharmacol Res 156, 104802), although success has been limited because glucocorticoid-induced immunosuppression may also depend on the transactivation of anti-inflammatory genes, and some side effects are also due to transrepressive activity (Clark, 2007, Anti-inflammatory functions of glucocorticoid-induced genes.Mol Cell Endocrinol 275, 79-97; Smoak and Cidlowski, 2004, Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 125, 697-706; Vandewalle et al., 2018, Therapeutic Mechanisms of Glucocorticoids. Trends Endocrinol Metab 29, 42-54). Therefore, it is interesting to try novel approaches to develop glucocorticoid drugs with fewer side effects, such as modifying the structure of existing GCs. For example, anti-CD163-dexamethasone conjugates designed to target activated macrophages have shown improved therapeutic rates in rats (Thomsen et al., 2016, Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats. World J Hepatol 8, 726-730), and conjugation of hydrolyzable polyethylene glycol (PEG) to prednisolone increases lung retention time in rats and therefore does not cause systemic side effects (Bayard et al., 2013, Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung. J Control Release 171, 234-240). Furthermore, the addition of γ-lactones or cyclic carbonates can make glucocorticoids more susceptible to inactivation by certain enzymes once they enter the bloodstream (Biggadike et al., 2000, Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J Med Chem 43, 19-21). .
[0005] Thus, there is a need for improved corticosteroid-type compounds. In particular, it would be beneficial to provide useful prodrugs that have limited activity (such as anti-inflammatory or anti-cancer agents) until converted to the active form. Summary of the Invention
[0006] The present invention provides compounds comprising a monosaccharide or disaccharide and an anti-inflammatory or chemotherapeutic moiety, as well as pharma- ceutically acceptable salts, stereoisomers, acids, or solvates thereof, which may be substrates for glucosylceramidase beta 2 (GBA2), such that the compounds are prodrugs that provide the active compound following cleavage of the monosaccharide or disaccharide by GBA2.
[0007] We have already mentioned that such glycosylated compounds may be relatively inactive until their sugar groups are removed, for example, by GBA2. The enzyme GBA2 is preferentially expressed in inflamed tissues (many cancer tissues also show inflammation). This means that anti-inflammatory and chemotherapeutic compounds can be converted into prodrugs by adding mono- or disaccharide moieties that can be cleaved by GBA2 at or near the site of inflammation, providing active anti-inflammatory or chemotherapeutic compounds in inflamed tissues. This provides a novel approach to direct therapeutic activity to the vicinity of target tissues, reducing off-target effects.
[0008] In a first aspect, the present invention provides a compound of formula I: [ka] or a pharma- ceutically acceptable salt, stereoisomer, acid or solvate thereof. A is selected from monosaccharides and disaccharides. B is a therapeutic moiety and may be suitably selected from an anti-inflammatory moiety or a chemotherapeutic moiety.
[0009] In the second aspect of the present invention, a pharmaceutical composition is provided that comprises the compound of the first aspect.The composition can be formulated for parenteral administration.For example, the composition can be formulated for parenteral administration, for example, the composition can be formulated for injection.
[0010] In a third aspect, there is provided a compound of the first aspect or a composition of the second aspect for use as a medicament. The medicament may be for use in treating a condition associated with inflammation. The medicament may be for use in treating a condition associated with inflammation by local conversion of a prodrug at the site of inflammation.
[0011] In a fourth aspect, there is provided a compound of the first aspect or the second composition for use in treating inflammation.
[0012] In a fifth aspect, there is provided a compound of the first aspect or a composition of the second aspect for use in the treatment of an inflammatory condition or other condition characterised by hyperactivity of the immune system.
[0013] In a sixth aspect, there is provided a compound of the first aspect or a composition of the second aspect for use in the treatment of a condition characterised by hyperproliferation of cells belonging to the immune system.
[0014] In a seventh aspect, there is provided a compound of the first aspect or the second composition for use in treating cancer.
[0015] In an eighth aspect, there is provided a use of the compound of the first aspect as an anti-inflammatory agent, comprising contacting the compound with a cell expressing glucosylceramidase beta 2 (GBA2). The contacting may be performed in vitro. The contacting may be performed in vivo. [Brief description of the drawings]
[0016] Embodiments of the invention are further described below with reference to the accompanying drawings.
[0017] [Figure 1] FIG. 1 shows the anti-inflammatory effect of ginsenosides via activation of GR. A. Schematic overview of the experimental approach used in the present assay. Zebrafish larvae were wounded at 74 hpf on the tail. Chemical compound treatment was started 2 hours before wounding and continued for 4 hours after wounding. At this time, the number of neutrophils migrating into the wound (shown in red box) was measured. B. Structures of compounds used for treatment: beclomethasone (Bec), protopanaxadiol (PPD), F2 and Rb1. Glucose (Glc) groups conjugated to the steroid backbone are shown in red. C. Number of migrating neutrophils upon compound treatment in wild-type (gr+ / +) and Gr-deficient (gr- / -) individuals. D. Relative mRNA levels of il1b, il6 and mmp9 measured by qPCR before and after wounding and upon compound treatment. E-H. Number of migrating neutrophils upon compound treatment in the absence and presence of the nonspecific chemical Gba inhibitor miglustat (E), the absence and presence of the Gba1 inhibitor ME656 (F), the absence and presence of the Gba2 inhibitor MZ31 (G), and in Gba2-deficient (gba2- / -) individuals (H). Data shown are means ± SEM of pooled data from three independent experiments in (C and E-H) or means ± SEM of three individual experiments in (D). Statistical significance was determined by one-way or two-way ANOVA and Tukey's post hoc test. Significant differences from the corresponding Veh groups (grey bars, C, E, F, G, H) are indicated by *** (P<0.001), significant differences from the corresponding gr+ / + (C) or same compound / Veh (E, G) groups (same color bars, no hatching) are indicated by ### (P<0.001), and significant differences from the non-wounded / Veh group (D) are indicated by +++ (P<0.001).
[0018] [Diagram 2] Figure 2 shows the number of migrating neutrophils and macrophages in wild-type zebrafish larvae treated with Bec, PPD, F2, or Rb1. Data shown are the mean ± SEM of pooled data from three independent experiments. Statistical significance was determined by one-way or two-way ANOVA and Tukey's post-hoc test. Significant differences from the Veh group are indicated by *** (P < 0.001).
[0019] [Diagram 3]FIG. 3 shows a comparison of side effects observed with beclomethasone to those observed with various ginsenosides. A. Whole body glucose levels measured by ELISA in 5 day post fertilization (dpf) zebrafish larvae treated with beclomethasone or the ginsenosides PPD, F2 or Rb1 from 2 hpf. B. Whole body glucose levels in 5 dpf larvae, wounded at 2 dpf and treated with compounds with or without MZ31. C. Whole body cortisol levels measured by ELISA in 5 day post fertilization (dpf) zebrafish larvae treated with beclomethasone or the ginsenosides PPD, F2 or Rb1 from 2 hpf. D. Whole body cortisol levels in 5 dpf larvae, wounded at 2 dpf and treated with compounds with or without MZ31. E. Body length in 5 dpf zebrafish larvae, wounded at 2 dpf and treated with compounds with or without MZ31 from 2 hpf. F. Regenerated caudal fin length of 5 dpf larvae wounded at 2 dpf upon compound treatment with or without MZ31. G. Relative GFP fluorescence levels after 24 h of compound treatment in 3 dpf larvae of Tg(9x GCRE-HSV.UI23:EGFP) strain, a reporter line for Gr transactivation activity. H. Representative bright field micrographs of caudal fins of 5 dpf larvae from the experimental group shown in F. I. Representative fluorescent micrographs of 3 dpf larvae from the experimental group shown in G. Data show the mean ± SEM of three independent experiments. Statistical significance was determined by one-way or two-way ANOVA and Tukey's post-hoc test. Significant differences from the corresponding Veh groups (A-F, H, grey bars) are indicated with * (P<0.05), ** (P<0.01), *** (P<0.001); differences from the same compound / Veh groups (E, G, same color bars, no hatching) are indicated with # (P<0.05), ## (P<0.01), ## (P<0.001); differences from the corresponding F2- and Rb1-treated groups (C, D, H) are indicated with ++ (P<0.001).
[0020] [Figure 4]Figure 4 shows the additional effect of beclomethasone treatment on regenerated tail fin length and mRNA levels in zebrafish larvae in comparison with various ginsenosides. A. Regenerated tail fin length of 5 dpf larvae wounded at 2 dpf and treated with various concentrations of Bec. B. Relative mRNA levels of fkbp5, pck1, nfkbiaa measured by qPCR before and after wounding and upon compound treatment. Data shown are mean ± SEM of three independent experiments. Statistical significance was determined by one-way or two-way ANOVA and Tukey's post-hoc test. Significant differences from the corresponding Veh group are indicated by *** (P<0.001) and differences from PPD-, F2- and Rb1-treated groups are indicated by ++ (P<0.001).
[0021] [Diagram 5] Figure 5 shows the effect of wounding on the mRNA levels, protein levels and enzyme activity of Gba1 and Gba2 in the zebrafish larvae tested. A. Relative mRNA levels of gba1 and gba2 measured by qPCR in control larvae and 4 hours after wounding at 5 dpf. B. Relative protein levels of Gba1 and Gba2 determined by the intensity of the bands (shown in Figure S3A) in an activity-based probe assay in control larvae and 4 hours after wounding at 5 dpf. C. Relative protein levels of Gba1 and Gba2 in the anterior and posterior parts of the body of control and wounded larvae. D. Enzyme activity of Gba2 (expressed per mg of protein) measured in lysates from control and wounded larvae at 5 dpf. Data shown are means ± SEM of three independent experiments. Statistical significance was determined by one-way ANOVA or two-way ANOVA and Tukey's post hoc test. Significant differences from the corresponding control group are indicated by ** (P<0.01), *** (P<0.001), and significant differences from the corresponding anterior group are indicated by ### (P<0.01).
[0022] [Figure 6]FIG. 6 shows further evidence of the effect of wounding on enzyme activity, protein levels, and mRNA levels, as well as gels generated by activity-based probe assays. A. Representative images of gels generated by activity-based probe assays showing experimental groups shown in FIG. 3B. B. Representative images of gels generated by activity-based probe assays showing experimental groups shown in FIG. 3C. C. Enzyme activity of Gba2 measured in lysates from control and 5 dpf wounded larvae (expression per zebrafish larva). D. Relative mRNA levels of gba1 and gba2 measured by qPCR in HeLa cells after control treatment and 6 hours of TNF-α treatment. E. Representative images of gels generated by activity-based probe assays showing experimental groups shown in FIG. F. Relative protein levels of Gba1 and Gba2 measured by activity-based probe assays in HeLa cells after control treatment and 6 hours of TNF-α treatment. Data shown are mean ± SEM of three independent experiments. Statistical significance was determined by one-way or two-way ANOVA with Tukey's post-hoc test. Significant differences from the corresponding control groups are indicated by ** (P<0.01), *** (P<0.001).
[0023] [Figure 7]Figure 7 shows the anti-inflammatory activity and associated side effects of glucuronidated dexamethasone (GDex) compared to other compounds. A. Number of migrating neutrophils and macrophages in wild-type zebrafish larvae treated with Bec, dexamethasone (Dex) and glucuronidated dexamethasone (GDex) at 4 hours after wounding. B. Number of migrating neutrophils in Gr-deficient (gr- / -) individuals upon compound treatment. C. Relative mRNA levels of il1b, il6, mmp9 and mmp13 measured by qPCR before and after wounding and upon compound treatment. D. Whole-body glucose levels measured by ELISA in 5-day post-fertilization (dpf) zebrafish larvae treated with Bec, Dex or G-Dex from 2 hpf. E. Whole body cortisol levels measured by ELISA in 5 day post fertilization (dpf) zebrafish larvae treated with Bec, Dex or GDex from 2 hpf. F. Regenerated caudal fin length upon compound treatment in 5 dpf larvae wounded at 2 dpf. G. Relative GFP fluorescence levels after 24 h compound treatment in 3 dpf larvae from Tg(9x GCRE-HSV.UI23:EGFP) line. H. Relative mRNA levels of fkbp5, pck1 and nfkbiaa measured by qPCR before and after wounding and upon compound treatment. Data shown are mean ± SEM of pooled data from three independent experiments (AB) or mean ± SEM of three independent experiments (CH). Statistical significance was determined by one-way or two-way ANOVA with Tukey's post hoc test. Significant differences from the corresponding Veh groups are indicated by * (P<0.05), ** (P<0.01), *** (P<0.001), and differences from the Bec (if present) and Dex treated groups are indicated by +++ (P<0.001).
[0024] [Figure 8]Figure 8 shows the anti-inflammatory activity and side effects of glucosidized prednisolone (GPdn) compared to other compounds. A. Number of migrating neutrophils upon treatment with Bec, Dex, GDex, prednisolone (Pdn) and glucosidized prednisolone (GPdn) in the absence and presence of the Gba2 inhibitor MZ31. B. Whole body glucose levels measured by ELISA in 5 day post fertilization (dpf) zebrafish larvae treated with Bec, Dex, G-Dex, Pdn or G-Pdn from 2hpf. C. Whole body glucose levels of 5dpf larvae wounded at 2dpf and treated with compounds with or without MZ31. D. Whole body cortisol levels measured by ELISA in 5 day post fertilization (dpf) zebrafish larvae treated with Bec, Dex, G-Dex, Pdn, G-Pdn from 2 hpf. E. Whole body cortisol levels in 5 dpf larvae wounded at 2 dpf and treated with compounds with or without MZ31. Data shown are means ± SEM of pooled data from three independent experiments (A) or means ± SEM of three independent experiments (performed in triplicate) in B-E. Statistical significance was determined by one-way or two-way ANOVA with Tukey's post hoc test. Significant differences from the corresponding Veh group (grey bars) are indicated by * (P<0.05), *** (P<0.001), significant differences from the corresponding groups treated with non-glycosidic compounds (Dex or Pdn) are indicated by +++ (P<0.001), and significant differences from the Veh group of MZ31-treated groups (same color, unhatched bars) are indicated by # (P<0.05), ### (P<0.001).
[0025] [Figure 9]Figure 9 shows the anti-inflammatory activity and associated side effects of gentiobiosidated prednisolone (GbPdn) compared to glucosidated prednisolone and prednisolone. A. Structures of compounds used in treatment: prednisolone (Pdn), glucosidated prednisolone (GPdn) and gentiobiosidated prednisolone (GdPdn). Glucose (Glc) and gentiobiose (Gb) groups conjugated to the steroid backbone of Pdn are shown in red. B. Number of migrating neutrophils upon treatment with Pdn, GPdn and gentiobiosidated Pdn (GbPdn) in the absence and presence of the Gba2 inhibitor MZ31. C. Relative mRNA levels of il1b, il6 and il8 measured by qPCR before and after wounding and upon compound treatment. D. Whole body glucose levels measured by ELISA in control and injured zebrafish larvae treated with Pdn, GPdn or GbPdn from 2hpf to 5dpf. E. Whole body glucose levels measured by ELISA in control and injured zebrafish larvae treated with Pdn, GPdn or GbPdn from 2hpf to 5dpf, with control treatment or overexpression of gba2 using CMV:gba2 plasmid. F. Whole body cortisol levels measured by ELISA in control and injured zebrafish larvae treated with Pdn, GPdn or GbPdn from 2hpf to 5dpf. G. Whole body cortisol levels measured by ELISA in control and injured zebrafish larvae treated with Pdn, GPdn or GbPdn from 2hpf to 5dpf, with control treatment or overexpression of gba2 using CMV:gba2 plasmid. Shown are the means ± SEM of pooled data from three independent experiments (B) or the means ± SEM of three independent experiments (CG). Statistical significance was determined by one-way or two-way ANOVA and Tukey's post-hoc test.Significant differences from the corresponding Veh group (grey bars) are indicated with * (P<0.05), ** (P<0.01), ** (P<0.001); significant differences from the corresponding Pdn-treated group (pink bars) are indicated with +++ (P<0.001); significant differences of MZ31-treated groups (B) from the Veh group, wound control groups (D, F) or CMV:gba2 groups (E, G) are indicated with # (P<0.05), ## (P<0.01), ### (P<0.001).
[0026] [Figure 10]FIG. 10 shows the additional effects of treatment of zebrafish larvae with gentiobiosidated prednisolone (GbPdn), glucosidated prednisolone (GPdn) and prednisolone (Pdn). A. Regenerated caudal fin length of 5 dpf larvae wounded at 2 dpf and treated with various concentrations of Pdn. B. Relative gba2 mRNA levels measured by qPCR in control larvae and after overexpression of gba2 using CMV:gba2 plasmid. C. Body length of 5 dpf zebrafish larvae treated with compounds from 2 hpf. D. Regenerated caudal fin length of 5 dpf larvae wounded at 2 dpf and treated with compounds with or without MZ31. E. Relative GFP fluorescence levels in 3 dpf larvae from Tg(9x GCRE-HSV.UI23:EGFP) strain after 24 h compound treatment. F. Relative GFP fluorescence levels in 3 dpf larvae from Tg(9x GCRE-HSV.UI23:EGFP) strain after overexpression of gba2 using CMV:gba2 plasmid after 24 h compound treatment. G. Representative fluorescence microscopy images of selected 3 dpf larvae from experimental groups shown in E-F. H. Relative mRNA levels of fkbp5, pck1 and nfkbiaa measured by qPCR before and after wounding and upon compound treatment. I. Relative mRNA levels of fkbp5, pck1 and nfkbiaa in the presence or absence of gba2 overexpression (using CMV:gba2 plasmid) and upon compound treatment. Data shown are mean ± SEM of three independent experiments. Statistical significance was determined by one-way or two-way ANOVA with Tukey post-hoc test. Significant differences from the corresponding Veh group (gray bars) are indicated by *** (P<0.001), significant differences from the corresponding Pdn-treated group (pink bars) are indicated by +++ (P<0.001), and significant differences from the corresponding MZ31-treated group (D, unhatched bars of the same color) are indicated by ### (P<0.001).
[0027] [Figure 11]FIG. 11 shows the comparative effects of in vitro human cell treatment with gentiobiosidated prednisolone (GbPdn), glucosidated prednisolone (GPdn) and prednisolone (Pdn). A. In vitro measurement of relative binding affinity using the PolarScreen glucocorticoid receptor (GR) competition assay. Fluorescence polarization levels are plotted reflecting binding of fluorescent ligands competed from the receptor by increasing concentrations of compounds Dex, Pdn, G-Pdn and Gb-Pdn. IC50 levels of each compound are shown. B. Nuclear translocation levels of GR in HeLa cells treated with Pdn, GPdn and GbPdn, measured using immunocytochemistry and confocal microscopy in the absence and presence of TNF-α and / or MZ31. C-F. Relative mRNA levels of IL1B (C), IL8 (D), FKBP5 (E) and NFKBIA (F) in HeLa cells after 6 h treatment with Pdn, G-Pdn or Gb-Pdn in the presence and absence of TNF-α and / or MZ31, as measured by qPCR. G. Relative mRNA levels of FKBP5 in HeLa cells after 6 h treatment with Pdn, G-Pdn or Gb-Pdn in the absence and presence of TNF-α, and after lentivirus-mediated shRNA knockdown of GBA1 or GBA2. H. Relative mRNA levels of FKBP5 and NFKBIA in HeLa cells after 6 h treatment with Pdn, G-Pdn or Gb-Pdn after overexpression of GBA2 by transfection of CMV:GBA2 plasmid. Data shown are the mean ± SEM of three independent experiments. Statistical significance was determined by one-way or two-way ANOVA with Tukey's post-hoc test. Significant differences from the corresponding Veh group (gray bars) are indicated by * (P < 0.05), ** (P < 0.01), *** (P < 0.001), significant differences from the Pdn-treated group (pink bars) are indicated by + (P < 0.05), ++ (P < 0.01), +++ (P < 0.001), and significant differences of the MZ31-treated group (B, unhatched bars of the same color) treatment group from the Veh group are indicated by ## (P < 0.01).
[0028] [Figure 12] Figure 12 shows further effects of in vitro treatment of human cells with gentiobiosidated prednisolone (GbPdn), glucosidated prednisolone (GPdn) and prednisolone (Pdn). A. Representative confocal microscopy images showing nuclear translocation of GR (green fluorescence) in HeLa cells for the experimental groups shown in Figure 11B. Nuclear DAPI staining is shown in blue. B-D. Relative mRNA levels of MMP13 (B), GILZ (C) and SGK1 (D) in HeLa cells after 6 h treatment with Pdn, GPdn or GbPdn in the absence and presence of TNF-α and / or MZ31, as measured by qPCR. E. Relative mRNA levels of NFKBIA in HeLa cells in the absence and presence of TNF-α, after 6 h treatment with Pdn, GPdn, or GbPdn, and after lentivirus-mediated shRNA knockdown of GBA1 or GBA2. Data shown are the mean ± SEM of three independent experiments. Statistical significance was determined by one-way or two-way ANOVA and Tukey's post-hoc test. Significant differences from the corresponding Veh group (gray bars) are indicated by ** (P < 0.01), *** (P < 0.001), and significant differences from the corresponding Pdn-treated group (pink bars) are indicated by ++ (P < 0.01), +++ (P < 0.001).
[0029] [Figure 13] Figure 13 provides a schematic overview of the procedures followed in a collagen antibody-induced arthritis (CAIA) mouse model experiment. Mice received the CAIA cocktail on day 1, followed by LPS treatment on day 4. Prednisolone (Pdn) or gentiobiosidized prednisolone (GbPdn) treatment was given daily from days 7 to 15.
[0030] [Figure 14]FIG. 14 shows the therapeutic effects and side effects obtained with prednisolone (Pdn) and gentiobiosidized prednisolone (GbPdn) in the CAIA model. A. Arthritis scores of mice measured daily from day 5 to day 15. B. Serum IL-6 levels measured by ELISA on days 10 and 15. C. Serum insulin levels measured by ELISA on day 14. D. Serum corticosterone levels measured by enzyme immunoassay on day 15. E. Liver tissue mRNA levels of Fkbp5, Pck1 and Gilz measured by qPCR on day 15. F. Muscle tissue mRNA levels of Redde1, Foxo3 and Klf15 on day 15. G. Gilz and Fkbp5 mRNA levels in hind ankle joint tissue on day 15. Statistically significant differences from the Veh group are indicated by *** (P<0.001).
[0031] [Figure 15] Figure 15 shows that Gba2 expressed close to the site of inflammation removes the entire gentiobiose group from gentiobiosidated prednisolone (GbPdn). GbPdn, glucosidated prednisolone (GPdn) and prednisolone (Pdn) concentrations were measured by LC-MS analysis in extracts from zebrafish larvae following tail wounding and treatment with 25 μM GbPdn (2 hours before wounding and 4 hours after wounding). A. Concentrations measured in extracts from control (unwounded) and wounded wild-type larvae treated with vehicle or the Gba2 inhibitor MZ31. B. Concentrations measured in extracts from control (unwounded) and wounded gba2- / - larvae. Statistically significant differences from the control / Veh group are indicated by *** (P<0.001).
[0032] Detailed Description Throughout the description and claims of this specification, the terms "comprise" and "contain" and variations thereof mean "including, but not limited to," and are not intended to (and do not) exclude other moieties, additives, components, integers, or steps. Throughout the description and claims of this specification, the singular includes the plural, unless the context requires otherwise. In particular, when the indefinite article is used, the specification is understood to contemplate the plural as well as the singular, unless the context requires otherwise.
[0033] It is understood that any feature, integer, property, compound, chemical moiety or chemical group described in connection with a particular aspect, embodiment or example of the invention is also applicable to other aspects, embodiments or examples described herein, except where inconsistent therewith. All of the features disclosed herein (including the accompanying claims, abstract and drawings), and / or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. The invention is not limited to the details of the foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed herein (including the accompanying claims, abstract and drawings), or any novel one, or any novel combination of the steps of any method or process so disclosed.
[0034] The reader is directed to all articles and documents related to this application that have been filed contemporaneously or prior to this application and are published herewith, the contents of all such articles and documents being incorporated herein by reference.
[0035] definition The following explanations of terms and methods are provided to better describe the present disclosure and to guide those skilled in the art in the practice of the present disclosure.
[0036] The present invention relates, inter alia, to the treatment of disease. The term "treatment" and the therapy encompassed by the present invention includes the following and combinations thereof: (1) preventing, e.g., delaying, the onset and / or progression of an event, condition, disorder or symptom, e.g., arresting, reducing or delaying the occurrence of an event, condition, disorder or symptom, or its recurrence in the case of treatment maintenance or secondary prevention, or at least one clinical or subclinical symptom thereof; (2) preventing or delaying the appearance of clinical symptoms of an event, condition, disorder or symptom in an animal (e.g., human), where the animal may suffer from or is susceptible to the condition, disorder or symptom, but has not yet experienced or exhibited clinical or subclinical symptoms of the condition, disorder or symptom; and / or (3) alleviating and / or curing an event, condition, disorder or symptom (e.g., causing the regression of an event, condition, disorder or symptom, or at least one clinical or subclinical symptom thereof, curing the patient, or putting the patient into remission). The benefit to the treated patient may be statistically significant or at least perceptible to the patient or physician. It will be understood that a medicine will not necessarily produce a clinical effect in each patient to which it is administered. Thus, in an individual patient, or even in a particular patient population, treatment may only partially fail or succeed, and the meaning of the terms "treatment" and "prevention", as well as similar terms, must be understood accordingly. The compositions and methods described herein are used for the treatment and / or prevention of the above-mentioned conditions.
[0037] The term "prevention" includes reference to treatment therapy that aims to maintain health or inhibit or delay the onset and / or progression of an event, condition, disorder or condition, for example, to reduce the likelihood of the occurrence of the event, condition, disorder or condition. The result of prevention is, for example, to maintain health or delay the onset and / or progression of an event, condition, disorder or condition. Treatment may fail in individual patients or even in certain patient populations, and this paragraph should be understood accordingly.
[0038] The term "alkyl" as used herein includes reference to straight or branched chain alkyl moieties having up to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms. This term includes, for example, methyl, ethyl, propyl (n-propyl or isopropyl), butyl (n-butyl, sec-butyl or tert-butyl), pentyl, hexyl, and the like. In particular, alkyl may be "C1-C8 alkyl", i.e., alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; "C1-C6 alkyl", i.e., alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms; "C1-C4 alkyl", i.e., alkyl having 1, 2, 3 or 4 carbon atoms; or "C1-C3 alkyl", i.e., alkyl having 1, 2 or 3 carbon atoms. The term "lower alkyl" includes reference to alkyl groups having 1, 2, 3 or 4 carbon atoms.
[0039] The term "alkenyl" as used herein includes reference to straight or branched chain alkenyl moieties having up to 20 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms. This term includes reference to, for example, ethenyl, propenyl, butenyl, pentenyl, hexenyl, and the like. In particular, alkenyl can be "C3-C8 alkenyl", i.e., alkenyl having 3, 4, 5, 6, 7 or 8 carbon atoms; "C3-C6 alkyl", i.e., alkenyl having 3, 4, 5 or 6 carbon atoms; "C3-C4 alkyl", i.e., alkenyl having 3 or 4 carbon atoms, and the term "lower alkenyl" includes reference to alkyl groups having 2, 3 or 4 carbon atoms. Alkenyl can be monounsaturated (i.e., containing a single carbon-carbon double bond) or polyunsaturated (i.e., containing two or more carbon-carbon double bonds, e.g., containing 2, 3 or 4 carbon-carbon double bonds). For example, alkenyl can be alkadienyl, alktrienyl, and the like.
[0040] The term "cycloalkyl" as used herein includes references to alicyclic moieties having 3, 4, 5 or 6 carbon atoms. The group may be a bridged or polycyclic ring system. More often, cycloalkyl groups are monocyclic. The term includes references to groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
[0041] The term "heteroalkyl," by itself or in combination with other terms, means, unless otherwise specified, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, containing at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, wherein the nitrogen and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heteroatoms O, N, P, S, and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, -CH-CH-O-CH, -CH-CH-NH-CH, -CH-CH-N(CH)-CH, -CH-S-CH-CH, -CH-CH,-S(O)-CH, -CH-CH-S(O)-CH, -CH=CH-O-CH, -Si(CH), -CH-CH=N-OCH, -CH=CH-N(CH)-CH, O-CH, -O-CH-CH, and -CN. Similarly, the term "heteroalkylene" by itself or as part of another substituent means a divalent radical derived from heteroalkyl, exemplified by, but not limited to, -CH-CH-S-CH-CH- and -CH-S-CH-CH-NH-CH-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). Additionally, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula: -C(O)2R'- represents both -C(O)2R'- and -R'C(O)2-. As noted above, heteroalkyl groups as used herein include groups that are linked to the remainder of the molecule through a heteroatom, e.g., -C(O)R', -C(O)NR', -NR'R'', -OR', -SR', and / or -SOR'.When "heteroalkyl" is described and then a specific heteroalkyl group, such as -NR'R'', it will be understood that the terms heteroalkyl and -NR'R'' are not redundant or mutually exclusive. Rather, the specific heteroalkyl group is described to add clarity. Thus, the term "heteroalkyl" should not be construed herein as excluding a specific heteroalkyl group, such as -NR'R''.
[0042] The term "heterocycloalkyl" as used herein includes references to saturated heterocyclic moieties having 3, 4, 5, 6 or 7 ring carbon atoms and 1, 2, 3, 4 or 5 ring heteroatoms selected from nitrogen, oxygen, phosphorus and sulfur. For example, heterocycloalkyl can include 3, 4 or 5 ring carbon atoms and 1 or 2 ring heteroatoms selected from nitrogen and oxygen. The group may be a polycyclic ring system, but is often monocyclic. The term includes references to groups such as azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, oxiranyl, pyrazolidinyl, imidazolyl, indolizinyl, piperazinyl, thiazolidinyl, morpholinyl, thiomorpholinyl, quinolizidinyl, and the like.
[0043] As used herein, the term "halo" or "halogen" includes reference to F, Cl, Br or I, e.g., F, Cl or Br. In a particular class of embodiments, the halogen is F or Cl, with F being more common.
[0044] The term "halo" or "halogen," by itself or as part of another substituent, means, unless otherwise specified, a fluorine, chlorine, bromine, or iodine atom; for example, halo can be fluorine, chlorine, or bromine. Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by the corresponding number of halogens. For example, the term "halo(C1-C4)alkyl" is meant to include, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
[0045] The term "alkoxy" as used herein includes reference to -O-alkyl, where alkyl is straight or branched and contains 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms. In one class of embodiments, alkoxy has 1, 2, 3 or 4 carbon atoms, e.g., 1, 2 or 3 carbon atoms. This term includes reference to, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentoxy, hexoxy, and the like. The term "lower alkoxy" includes reference to alkoxy groups having 1, 2, 3 or 4 carbon atoms.
[0046] The term "haloalkoxy," as used herein, refers to an alkoxy group in which one or more hydrogen atoms are replaced by the corresponding number of halogens.
[0047] Each of the above terms (e.g., "alkyl", "cycloalkyl", "heteroalkyl" and "alkoxyl") is meant to include both substituted and unsubstituted forms of the indicated radical unless otherwise specified. When a substituent is R-substituted (e.g., Rx-substituted alkyl, where "x" is an integer), the substituent may be substituted with one or more R groups, where each R group is optionally different, as permitted by the chemical valence rules (e.g., Rx-substituted alkyl may include multiple Rx groups, where each Rx group is optionally different). Specific examples of substituents for each type of radical are shown below.
[0048] The term "substituted" as used herein with respect to a moiety means that one or more, particularly 1 to 5, more particularly 1, 2 or 3, of the hydrogen atoms in said moiety are replaced independently from each other by the corresponding number of listed substituents. Unless otherwise specified, examples of substituents include -OH, -CN, -NH 2 , -NH(C1-C6 alkyl), -N(C1-C4 alkyl), =O, -halo, -C1-C6 alkyl, -C2-C6 alkenyl, -C1-C6 haloalkyl, -C1-C6 haloalkoxy and -C2-C6 haloalkenyl, -C1-C6 alkyl carboxylic acids (e.g., -CH 3 When the substituent is -C1-C6 alkyl or -C1-C6 haloalkyl, the C1-C6 chain is optionally interrupted by an ether bond (-O-) or an ester bond (-C(O)O-). Exemplary substituted alkyl substituents include -OH, -CN, -NH 2 , =O, -halo, -CO2H, -C1-C6 haloalkyl, -C1-C6 haloalkoxy and C2-C6 haloalkenyl, -C1-C6 alkyl carboxylic acid (e.g., -CH3COOH or -COOH). For example, exemplary alkyl substituents include -OH, -CN, -NH2, =O, -halo.
[0049] Of course, it will be understood that the substituents are present only in chemically possible positions, and that those skilled in the art can determine (experimentally or theoretically) whether a particular substituent is possible without undue effort. For example, an amino group or a hydroxy group having a free hydrogen may be unstable when attached to a carbon atom having an unsaturated (e.g., olefinic) bond. Furthermore, it will of course be understood that the substituents described herein may themselves be substituted with any substituent, subject to the above-mentioned restrictions on suitable substituents as recognized by those skilled in the art.
[0050] When steric issues dictate the configuration of substituents on a group, the isomer having the lowest conformational energy is preferred.
[0051] When a compound, moiety, process, or product is described as "optionally" having a certain feature, the disclosure includes the compound, moiety, process, or product having that feature, as well as the compound, moiety, process, or product without that feature. Thus, when a moiety is described as "optionally substituted," the disclosure includes the unsubstituted moiety as well as the substituted moiety.
[0052] When two or more moieties are described as being "independently" or "each independently" selected from a list of atoms or groups, this means that the moieties can be the same or different, and thus the identity of each moiety is independent of the identity of one or more other moieties.
[0053] The term "molecular radical" by itself or as part of another substituent means a monovalent radical derived from a indicated molecular species. For example, a molecular radical of a given molecular species corresponds to the radical remaining after a hydrogen atom or a hydroxyl group is abstracted from the given molecular species.
[0054] As used herein, the term "pharmacologically acceptable" includes reference to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human or animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. The term includes acceptability for both human and veterinary purposes.
[0055] The term "pharmaceutically acceptable salt" is meant to include salts of active compounds prepared with relatively non-toxic acids or bases, depending on the specific substituents found on the compounds described herein.When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either in neat form or in a suitable inert solvent.Examples of pharmaceutically acceptable base addition salts include sodium salts, potassium salts, calcium salts, ammonium salts, organic amino salts, magnesium salts, or similar salts.When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either in neat form or in a suitable inert solvent. Examples of pharma- ceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphate, dihydrogenphosphate, sulfuric, monohydrogensulfuric, hydroiodic or phosphoric acid, and those derived from relatively non-toxic organic acids such as acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, etc. Also included are salts of amino acids such as arginic acid, and salts of organic acids such as glucuronic and galacturonic acids (see, e.g., Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
[0056] The term "acid" in relation to the sugars constituting the compounds disclosed herein is meant to include those forms of the compounds in which the sugars (and / or at least one monosaccharide residue thereof) constitute a carboxylic acid. Such a carboxylic acid can form part of an aldonic acid or a uronic acid. An aldonic acid is obtained when the terminal aldehyde group of an aldo sugar is oxidized, e.g., oxidation of D-glucose at C1 gives D-gluconic acid. An uronic acid is obtained when the hydroxyl group furthest from the carbonyl group of a sugar is oxidized to a carboxylic acid, e.g., oxidation of D-glucose gives the corresponding uronic acid, D-glucoronic acid. Exemplary sugar acids include gluconic acid, glucuronic acid, galactonic acid, galacturonic acid, idonic acid, iduronic acid, altronic acid, altruronic acid; and their D- and L-enantiomers, such as D-gluconic acid, D-glucuronic acid, D-galactonic acid, D-galacturonic acid, L-idonic acid, and L-iduronic acid, L-altronic acid, L-altruronic acid, etc.
[0057] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
[0058] Certain compounds of the present invention can exist not only in nonsolvated form but also in solvated form, including hydrated form.In general, solvated form is equivalent to nonsolvated form and is included in the scope of the present invention.Certain compounds of the present invention can exist in multiple crystalline or amorphous forms.In general, all physical forms are equivalent for the use contemplated by the present invention and are intended to be within the scope of the present invention.
[0059] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, tautomers, geometric isomers and individual isomers are encompassed within the scope of the present invention. Compounds of the present invention do not include those known in the art to be too unstable to synthesize and / or isolate.
[0060] The term "prodrug" as used herein refers to a compound that is converted into a parent compound or other active compound in vivo, for example by hydrolysis in blood. An example of such a prodrug is a pharma- ceutically acceptable ester of a carboxylic acid. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the ACS Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987; H Bundgaard, ed., Design of Prodrugs, Elsevier, 1985; and Judkins, et al. Synthetic Communications, 26(23), 4351-4367 (1996); and The organic chemistry of drug design and drug action by Richard B Silverman in particular pages 497 to 546 (each of which is incorporated herein by reference). The compounds of the present invention may represent prodrugs (e.g., containing potential anti-inflammatory or anti-cancer agents) that provide active anti-inflammatory or anti-cancer agents upon hydrolysis of a monosaccharide or disaccharide moiety, e.g., by the action of GBA2.
[0061] As used herein, the term "pharmaceutical composition" includes reference to a composition that contains at least one active compound (or prodrug), and optionally one or more additional pharma- ceutically acceptable components, such as a pharma- ceutically acceptable carrier. Unless the context indicates otherwise, all references herein to a "composition" are references to a pharmaceutical formulation.
[0062] As used herein, the term "product" or "product of the invention" includes reference to any product containing a compound of the invention. In particular, the term product relates to a composition or formulation that contains a compound of the invention, such as a pharmaceutical composition.
[0063] As used herein, the term "therapeutically effective amount" means an amount of a drug or pharmaceutical agent that is calculated (or will provide) within the scope of sound pharmacological judgment to provide a desired therapeutic response in a mammal (animal or human), the therapeutic response serving, for example, to cure, slow the progression of, or prevent a disease, disorder, or condition.
[0064] The term "GBA2" as used herein refers to the enzyme glucosylceramidase beta 2, designated by the HUGO Gene Nomenclature Committee. This enzyme is a microsomal beta-glucosidase known to catalyze the hydrolysis of bile acid 3-O-glucosides. We have determined that the enzyme GBA2 is selectively expressed at sites of inflammation, such as sites of induced inflammation in zebrafish. Compounds provided herein that include a therapeutic moiety, e.g., an anti-inflammatory moiety or a chemotherapeutic moiety, covalently attached to a monosaccharide or disaccharide, such as compounds of Formula I or Formula II, can be hydrolyzed by GBA2 activity. Thus, GBA2 can selectively release an active therapeutic moiety, such as an anti-inflammatory agent or an active chemotherapeutic moiety, at the site of inflammation. Thus, the compounds of the present invention are suitable for use in targeted delivery of active therapeutic moieties, including, but not limited to, active anti-inflammatory agents or active chemotherapeutic moieties, to sites of inflammation. It is readily apparent that such targeted delivery to sites where inflammation occurs is beneficial for a wide range of treatment sites. Inflammation is a component of many pathological processes and conditions, and this approach can be used to deliver therapeutic moieties suitable for the treatment of such conditions (not just for the mitigation of inflammatory responses) by generating the active drug in situ from the prodrug compounds of the invention.
[0065] Although it is unclear which sugars mammalian GBA2 can cleave from lipophilic compounds such as cholesterol and steroid hormones, some findings, in addition to the results provided in this disclosure, indicate that there is a level of specificity available. GBA2 has been shown to cleave β-D-glucosylated compounds (i.e., compounds with a D-glucose group attached by a β-glycosidic bond) (Marques, et al. (2016). "Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular beta-glucosidases." J Lipid Res 57(3): 451-463). GBA2 also cleaves β-D-galactosylated compounds (Akiyama, et al. (2020). "Glucocerebrosidases catalyze a transgalactosylation reaction that yields a newly-identified brain sterol metabolite, galactosylated cholesterol." J Biol Chem 295(16): 5257-5277). In contrast, this is not the case for β-xylosidated compounds (Boer, et al. (2021). "Human glucocerebrosidase mediates formation of xylosyl-cholesterol by beta-xylosidase and transxylosidase reactions." J Lipid Res 62: 100018). Thus, GBA2 appears to be specific for aldohexoses.Further specificity may be possible within the aldohexose group, as observed in studies in which derivatives of the iminosugar deoxynojirimycin were tested as inhibitors of GBA2 (Wennekes, et al. (2010). "Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation." J Med Chem 53(2): 689-698; Ghisaidoobe, et al. (2014). "Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase / neutral glucosylceramidase inhibitors." J Med Chem 57(21): 9096-9104; Lahav, et al. (2017). "A Fluorescence Polarization Activity-Based Protein Profiling Assay in the Discovery of Potent, Selective Inhibitors for Human Nonlysosomal Glucosylceramidase.” J Am Chem Soc 139(40): 14192-14197). For example, based on these studies, it was suggested that L-idose also forms a potent substrate for GBA2 cleavage.
[0066] Previous studies have considered GBA2 to be an exoglycosidase, an enzyme that can only cleave monosaccharides from lipophilic compounds, however, in this application we demonstrate for the first time that GBA2 can actually remove disaccharides from steroid molecules, thereby suggesting that GBA2 is in fact an endoglycosidase, capable of cleaving disaccharide moieties from lipophilic compounds such as corticosteroids.
[0067] As used herein, the term "corticosteroids" refers to a class of steroid hormones that includes naturally occurring corticosteroids produced by vertebrates and synthetic analogs of such compounds. As with other steroid molecules, the carbon atoms of corticosteroids are numbered based on the following hypothetical parent backbone structure: [ka] A preferred group of corticosteroids are the glucocorticoids, which often have anti-inflammatory activity. The anti-inflammatory effect can be mediated by reducing the levels of pro-inflammatory mediators (e.g., by transrepression of gene expression) and / or by increasing the levels of anti-inflammatory mediators (e.g., by transactivation of gene expression).
[0068] compound In one aspect, the present invention provides a compound of formula I as described above, or a pharma- ceutically acceptable salt, stereoisomer, solvate or prodrug thereof. These compounds may represent prodrugs in which the glycosylated compounds have reduced biological activity compared to the corresponding aglycosylated (i.e. non-glycosylated) compounds.
[0069] In the compound of formula I, A can be selected from glucose, galactose, mannose, fructose, and any of their acid forms, and disaccharides formed from one or two sugars selected from glucose, galactose, mannose, fructose, and any of their acid forms. The acid forms of glucose, galactose, mannose, and fructose can be aldonic acids or uronic acids; for example, the acid forms of glucose, galactose, mannose, and fructose can be uronic acids, such as glucuronic acid. Aldonic acids are obtained when the terminal aldehyde group of an aldo sugar is oxidized, for example, oxidation of D-glucose at C1 gives D-gluconic acid. Uronic acids are obtained when the hydroxyl group furthest from the carbonyl group of a sugar is oxidized to a carboxylic acid, for example, oxidation of D-glucose gives the corresponding uronic acid, D-glucoronic acid.
[0070] In the compound of formula I, A can be an aldohexose. A can be selected from glucose, galactose, idose, altrose and any of their acid forms, and disaccharides formed from one or two sugars selected from glucose, galactose, idose, altrose and any of their acid forms. The acid forms of glucose, galactose, idose, altrose can be aldonic acids or uronic acids; for example, the acid forms of glucose, galactose, idose, altrose can be uronic acids, such as glucuronic acid. Aldonic acids are obtained when the terminal aldehyde group of an aldosugar is oxidized, for example, D-glucose is oxidized at C1 to obtain D-gluconic acid. Uronic acids are obtained when the hydroxyl group furthest from the carbonyl group of a sugar is oxidized to a carboxylic acid, for example, D-glucose is oxidized to obtain the corresponding uronic acid, D-glucoronic acid. The position of the hydroxyl group at the C2 and / or C3 positions may affect the cleavage of GBA2 (van den Berg, et al. (2011). "Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors." ACS Med Chem Lett 2(7): 519-522). In this respect, A may be selected from D-glucose, D-galactose, L-idose, L-altrose and any acid form thereof, and disaccharides formed from one or two sugars selected from D-glucose, D-galactose, L-idose, L-altrose and any acid form thereof. The acid form of D-glucose, D-galactose, L-idose, L-altrose may be an aldonic acid or an uronic acid; for example, the acid form of D-glucose, D-galactose, L-idose, L-altrose may be an uronic acid, such as glucuronic acid.
[0071] In the compound of formula I, A can be a disaccharide formed from one or two of glucose, galactose, mannose, fructose, and any of their acid forms (e.g., aldonic acid or uronic acid). A can be a disaccharide formed from one or two of glucose, galactose, mannose, fructose, and any of their uronic acid forms. A can be a disaccharide formed from one or two of glucose, galactose, mannose, and fructose. For example, A can be gentiobiose. A can be a monosaccharide selected from glucose, galactose, mannose, fructose, and any of their acid forms (e.g., aldonic acid or uronic acid). A can be a monosaccharide selected from glucose, galactose, mannose, fructose, and any of their uronic acid forms. For example, A can be glucose or glucuronic acid. A can be a monosaccharide selected from glucose, galactose, mannose, and fructose. For example, A can be glucose.
[0072] In the compound of formula I, A can be a disaccharide formed from two aldohexoses. For example, A can be a disaccharide formed from one or two of glucose, galactose, idose, altrose, and any of their acid forms (e.g., aldonic acid or uronic acid). A can be a disaccharide formed from one or two of glucose, galactose, idose, altrose, and any of their uronic acid forms. A can be a disaccharide formed from one or two of glucose, galactose, idose, and altrose. For example, A can be gentiobiose. The position of the hydroxyl group at the C2 and / or C3 positions may affect the cleavage of GBA2 (van den Berg, et al. (2011).supra). In this respect, A can be a disaccharide formed from one or two of D-glucose, D-galactose, L-idose, L-altrose, and any of their acid forms (e.g., aldonic acid or uronic acid). A can be a disaccharide formed from one or two of each of D-glucose, D-galactose, L-idose, L-altrose, and their uronic acid forms. A can be a disaccharide formed from one or two of each of D-glucose, D-galactose, L-idose, and L-altrose. For example, A can be gentiobiose.
[0073] In some embodiments, disaccharides are preferred because disaccharide prodrugs may have reduced activity compared to the corresponding monosaccharide prodrugs, and both compounds provide the same activity of aglycosylated compounds.Therefore, compounds containing disaccharides and monosaccharides (after the sugar chain is removed) should provide the same level of on-target activity, while disaccharides can cause less side effects due to off-target activity.
[0074] In the compounds of formula I, B can be any therapeutic moiety whose biological activity can be reduced by the addition of a monosaccharide or disaccharide, as discussed above. Exemplary categories of therapeutic moieties include anti-inflammatory moieties, chemotherapeutic moieties, anti-infective moieties, analgesic moieties, anti-angiogenic moieties, and anti-fibrotic moieties.
[0075] Suitably, B may be an anti-inflammatory moiety. The anti-inflammatory moiety may be or comprise a corticosteroid (e.g., a glucocorticoid), a nonsteroidal glucocorticoid receptor agonist, a nonsteroidal anti-inflammatory, disease modifying antirheumatic drug, or rapamycin. The anti-inflammatory moiety may be or comprise a corticosteroid (e.g., a glucocorticoid). The anti-inflammatory moiety may be or comprise a nonsteroidal glucocorticoid receptor agonist. The anti-inflammatory moiety may be or comprise a nonsteroidal anti-inflammatory. The anti-inflammatory moiety may be or comprise a disease modifying antirheumatic drug. The anti-inflammatory moiety may be or comprise rapamycin.
[0076] The corticosteroid may be selected from hydrocortisone-type corticosteroids, triamcinolone acetonide-type corticosteroids, methasone-type corticosteroids, betamethasone dipropionate-type corticosteroids and methylprednisolone aceponate-type corticosteroids. The corticosteroid may be a hydrocortisone-type corticosteroid. The corticosteroid may be a triamcinolone acetonide-type corticosteroid. The corticosteroid may be a methasone-type corticosteroid. The corticosteroid may be a betamethasone dipropionate-type corticosteroid. The corticosteroid may be a methylprednisolone aceponate-type corticosteroid. These classes of corticosteroids are further defined below.
[0077] Four structural classes of corticosteroids have been defined based on cross-reactivity in corticosteroid-induced allergic contact dermatitis (Coopman and Dooms-Goossens, Cross-reactions in topical corticosteroid contact dermatitis. Contact Dermatitis. 1988 Aug;19(2):145-6; Coopman et al., Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol. 1989 Jul;121(1):27-34; Isaksson, Corticosteroids. Dermatol Ther. 2004;17(4):314-20; Jacob and Steele, Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. J Am Acad Dermatol. 2006 Apr;54(4):723-7.). The following paragraphs provide a description of each class of corticosteroids and their general structure. It should be noted that in these paragraphs regarding classes of corticosteroids, a reference to "Cnn," where "nn" is a number, is a reference to the indicated numbered carbon atom of the corticosteroid.
[0078] Class A: Hydrocorticone-type corticosteroids are those corticosteroids that have no substitutions on the D-ring or C11 carbon chain of the corticosteroid, but include the C11 and / or C21 acetate esters, and the C21 thioester tixocortol pivalate. [ka]
[0079] Class B: Triamcinolone acetonide-type corticosteroids are corticosteroids that have a C16, C17-cis, -diol, -ketal chain structure. [ka]
[0080] Class C: Betamethasone-type corticosteroids are corticosteroids with C16 alkyl substitution. [ka]
[0081] Class D: Hydrocortisone-17-butyrate type corticosteroids are corticosteroids that have long-chain esters at C17 and / or C21. [ka] Class D is further divided into two subclasses (Matura and Goossens, Reactions to corticosteroids: some new aspects regarding cross-sensitivity. Cutis. 2000 Jan;65(1):43-5; Goossens et al., Contact allergy to corticosteroids. Allergy. 2000 Aug;55(8):698-704), classes D1 and D2. Class D1, betamethasone dipropionate-type corticosteroids, includes corticosteroids with methyl substitution at C16, halogenation on the B ring, and long-chain esters at C17 and / or C21. Class D2, methylprednisolone aceponate-type corticosteroids, includes corticosteroids with no methyl substitution at C16, no halogenation, long side-chain esters at C17, and optionally a side chain at C21.
[0082] In the compounds of formula I, B is selected from the group consisting of alclometasone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, ciclometasone, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, cortifen, cortisol (hydrocortisone), cortisone, cortivazol, cortodoxone, dexamethasone, cyclometh ... Furazacort, desonide, desoximetasone, dexamethasone, dichlorisone, diflucortolone, diflorasone, difluprednate, formocortal, fluazacort, flucloronide, fludrocortisone, flucortin, flucortolone, flumethasone, flunisolide, fluocinolone, fluocinolone acetonide acetonide, fluocinonide, fluocortin, fluorometholone, fluperolone, fluprednidene, fluprednisolone, flurandrenolide, fluticasone, halcinonide, halobetasol, halometasone, hydrocortamate, icometasone, isoflurane, lotoprednol, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone, nicocortonide, paramethasone, prednicarbate, prednisolone, prednimustine, prednisone, procinonide, tixocortol, triamcinolone or triamcinolone acetonide, or an ester of any of them.The esters include acetate, adamantoate, benzoate, benzofurancarboxylate, benzoyl-β-aminoisobutyrate, butyrate, butyrate, caproate, carboxylate, chlorambucil, chlorphenacyl, cipecilate, cyclopentanepropionate, cyclopentylpropionate, cyclopropylcarboxylate, cypionate, dicibate, dichloroacetate, diethylaminoacetate, enanthate, embutate, ethoxylate ... It may be or include a group selected from tabonate (ethyl carbonate), fuorate, hemisuccinate, hexanoate, isobutyrate, isonicotinate, linoleate, metasulfobenzoate, metembonate, palmitate, phosphate, piperidinoacetate, pivalate, propionate, salicylate, stearoyl glycolate, succinate, suleptanate, sulfate, tert-butyl acetate, tetrahydrophthalate, troxundate, valerate, or xanthate groups.
[0083] In the compounds of formula I, B can be a chemotherapeutic moiety that can be or include the molecular radical of an alkylating agent (e.g., cisplatin), a nitrosourea (e.g., carmustine), antimetabolites (e.g., methotrexate and pentostatin), antineoplastic antibiotics (e.g., doxorubicin), a topoisomerase inhibitor (e.g., irinotecan), and a mitotic inhibitor (e.g., paclitaxel), or other chemotherapeutic agents that do not fall into these categories.
[0084] In the compound of formula I, B can be an anti-infective agent. In the compound of formula I, B can be an analgesic agent. In the compound of formula I, B can be an anti-angiogenic agent. In the compound of formula I, B can be an anti-fibrotic agent.
[0085] In one embodiment, the present invention provides a compound of formula II: [ka] or a pharma- ceutically acceptable salt, stereoisomer, acid or solvate thereof. R 1 is selected from monosaccharides or disaccharides. 2 is H, substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Alkoxy, substituted or unsubstituted C 3 -C 8 R is selected from alkenyl. 3 and R 4 are independently H, OH, C 1 -C 4 Substituted or unsubstituted alkyl, OR 9 , O.C.(O)R 9 or R 3 and R 4 R taken together with the carbon atom to which they are attached form a substituted or unsubstituted 5- or 6-membered heterocycloalkyl. 5 , R 6 , R 7 and R 8 each independently represents H, OH, halo, substituted or unsubstituted -C 1 -C 4 Alkyl or OR 10 Selected from: R 9 is H or -C 1 -C 8 substituted or unsubstituted alkyl. X is selected from =O or -OH.
[0086] X can be =O. X can be -OH.
[0087] The compound has formula IIIa or IIIb: [ka] or a pharma- ceutically acceptable salt, stereoisomer, acid or solvate thereof.
[0088] The compound has formula IVa or formula IVb: [ka] or a pharma- ceutically acceptable salt, stereoisomer or solvate thereof.
[0089] The compound has formula Va, formula Vb, formula Vc or formula Vd: [ka] or a pharma- ceutically acceptable salt, stereoisomer, acid or solvate thereof.
[0090] In each of formulas IIIa, IIIb, IVa, IVb, Va, Vb, Vc and Vd, the substituents are defined as follows: 1 is selected from monosaccharides or disaccharides. 2 is H, substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Alkoxy, substituted or unsubstituted C 3 -C 8 R is selected from alkenyl. 3 and R 4 are independently H, OH, C 1 -C 4 Substituted or unsubstituted alkyl, OR 9 , O.C.(O)R 9 or R 3 and R 4 R together with the carbon atom to which they are attached form a substituted or unsubstituted 5- or 6-membered heterocycloalkyl. 5 , R 6 , R 7 and R 8 each independently represents H, OH, halo, substituted or unsubstituted -C 1 -C 4Alkyl or OR 10 Selected from: R 9 is H or -C 1 -C 8 It is selected from substituted or unsubstituted alkyl.
[0091] In any of formulas II, IIIa, IIIb, IVa, IVb, Va, Vb, Vc, and Vd, the substituents may be further defined as follows:
[0092] R 1 may be selected from glucose, galactose, mannose, fructose and any acid form thereof, and any disaccharide formed from one or two saccharides selected from glucose, galactose, mannose, fructose and any acid form thereof. The acid forms of glucose, galactose, mannose, fructose may be aldonic acids or uronic acids; for example, the acid forms of glucose, galactose, mannose, fructose may be uronic acids, such as glucuronic acid.
[0093] R 1 can be selected from an aldohexose and a disaccharide formed from two aldohexoses, which may be the same or different. For example, R 1 may be selected from glucose, galactose, idose, altrose and any acid form thereof, and any disaccharide formed from one or two saccharides selected from glucose, galactose, idose, altrose and any acid form thereof. The acid form of glucose, galactose, idose, altrose may be aldonic acid or uronic acid; for example, the acid form of glucose, galactose, idose, altrose may be uronic acid, e.g., glucuronic acid. The position of the hydroxyl group at C2 and / or C3 position may affect the cleavage of GBA2 (van den Berg, et al. (2011), supra). In this regard, R 1may be selected from D-glucose, D-galactose, L-idose, L-altrose and any acid form thereof, and any disaccharide formed from one or two sugars selected from D-glucose, D-galactose, L-idose, L-altrose and any acid form thereof. The acid form of D-glucose, D-galactose, L-idose, L-altrose may be an aldonic acid or an uronic acid; for example, the acid form of D-glucose, D-galactose, L-idose, L-altrose may be an uronic acid, such as glucuronic acid.
[0094] R 1 R can be a disaccharide formed from one or two of glucose, galactose, mannose, fructose, and the acid form of any of these (e.g., aldonic acid or uronic acid). 1 R can be a disaccharide formed from glucose, galactose, mannose, fructose and one or two of each of the uronic acid forms of these. 1 can be a disaccharide formed from one or two of glucose, galactose, mannose, and fructose. For example, R 1 can be gentiobiose. 1 R can be a monosaccharide selected from glucose, galactose, mannose, fructose and the acid forms of any of these (e.g., aldonic or uronic acids). 1 can be a monosaccharide selected from glucose, galactose, mannose, fructose and the uronic acid forms thereof. For example, R 1 R can be glucose or glucuronic acid. 1 can be a monosaccharide selected from glucose, galactose, mannose and fructose. For example, R 1 can be glucose.
[0095] R 1 R can be a disaccharide formed from two aldohexoses, which may be the same or different. 1R can be a disaccharide formed from one or two of glucose, galactose, idose, altrose, and the acid form of any of these (e.g., aldonic acid or uronic acid). 1 R can be a disaccharide formed from one or two of glucose, galactose, idose, altrose, and their uronic acid forms. 1 can be a disaccharide formed from one or two of glucose, galactose, idose, and altrose. For example, R 1 may be gentiobiose. The position of the hydroxyl groups at C2 and / or C3 positions may affect the cleavage of GBA2 (van den Berg, et al. (2011), supra). From this perspective, R 1 R can be a disaccharide formed from one or two of D-glucose, D-galactose, L-idose, L-altrose, and any of the acid forms thereof (e.g., aldonic acid or uronic acid). 1 R can be a disaccharide formed from one or two of D-glucose, D-galactose, L-idose, L-altrose and their uronic acid forms. 1 can be a disaccharide formed from one or two of D-glucose, D-galactose, L-idose, and L-altrose. For example, R 1 can be gentiobiose.
[0096] R 1 Compounds in which R is a disaccharide may be preferred, as such compounds may exhibit reduced disaccharide prodrug activity compared to the corresponding monosaccharide prodrug, while both compounds provide aglycosylated compounds of similar activity. Thus, compounds containing disaccharides and monosaccharides should provide the same level of on-target activity (after removal of the monosaccharide or disaccharide moiety), while R 1 Compounds that are disaccharides may have fewer off-target side effects.
[0097] R 2is H and substituted or unsubstituted C 1 -C 8 R may be selected from alkyl. 2 can be H. R 2 is a substituted or unsubstituted C 1 -C 8 R can be alkyl. 2 is a substitution C 1 -C 8 R can be alkyl. 2 is unsubstituted C 1 -C 8 It may be alkyl.
[0098] R 3 are H, OH and OC(O)R 9 R 3 R may be selected from H and OH. 3 is H and OC(O)R 9 R 3 is OH and OC(O)R 9 R 3 can be H. R 3 can be OH. 3 is O.C.(O)R 9 It could be.
[0099] R 9 is a substituted or unsubstituted -C 1 -C 8 R can be alkyl. 9 Substitution -C 1 -C 8 R can be alkyl. 9 is unsubstituted -C 1 -C 8 It may be alkyl.
[0100] R 4 is H, OH or C 1 -C 4 R may be selected from alkyl. 4 R may be selected from H, OH or methyl. 4 can be H. R 4 can be OH. 4 is C 1 -C4 It may be alkyl (eg, methyl).
[0101] R 3 and R 4 may be taken together with the carbon atom to which they are attached to form a substituted or unsubstituted 5- or 6-membered heterocycloalkyl. For example, R 3 and R 4 R may combine with the carbon atom to which they are attached to form a substituted or unsubstituted 1,3 dioxolane. 3 and R 4 can be combined with the carbon atom to which they are attached to form a substituted 1,3 dioxolane. A 1,3 dioxolane is a -C 1 -C 4 The 2-position may be substituted with one or two groups selected from alkyl (e.g., methyl), 5- or 6-membered cycloalkyl, or 5- or 6-membered heterocyclic (e.g., furan). The 1,3 dioxolane is -C 1 -C 4 The 1,3 dioxolane may be substituted at the 2-position by one or two groups selected from alkyl, such as one or two methyl groups. The 1,3 dioxolane may be substituted at the 2-position by a 5- or 6-membered cycloalkyl. The 1,3 dioxolane may be substituted at the 2-position by a 5- or 6-membered heterocyclic, such as furan.
[0102] In certain compounds, R 2 is H and R 3 is OH and R 4 is H.
[0103] In certain compounds, R 2 is H and R 3 and R 4 together with the carbon atoms to which they are attached to form substituted or unsubstituted 1,3 dioxolanes.
[0104] In certain compounds, R 2 is H and R 4 is C 1 -C 4Alkyl (eg, methyl).
[0105] A specific compound, R 2 is H and R 3 is O.C.(O)R 9 and R 4 is H; optionally, where R 9 is substituted or unsubstituted -C 1 -C 8 It is an alkyl.
[0106] R 5 may be selected from H and halo. 5 may be selected from H, F and Cl. 5 can be H. R 5 can be F. R 5 can be Cl.
[0107] R 6 and R 7 may each be H.
[0108] R 8 may be selected from H and halo. 8 may be selected from H, F and Cl. 8 can be H. R 8 can be F. R 8 can be Cl.
[0109] R 10 is H or -C 1 -C 8 (For example, -C 1 -C 4 ) substituted or unsubstituted alkyl. R 10 can be H. R 10 -C 1 -C 6 (For example, -C 1 -C 4 ) may be substituted or unsubstituted alkyl.
[0110] The compound is [ka] and a pharma- ceutically acceptable salt, stereoisomer, acid or solvate thereof.
[0111] This compound may be a substrate for glucosylceramidase beta 2 (GBA2).
[0112] Compounds that are substrates for GBA2 have their sugar groups hydrolyzed by the activity of the enzyme GBA2. GBA2 activity can be determined using two different approaches, genetic and pharmacological, to 1) determine whether a particular effect of the compound depends on the presence and / or activity of this enzyme, and 2) determine in vitro whether a compound is converted by GBA2.
[0113] 1) To determine whether a particular effect of a compound depends on the presence and / or activity of GBA2, the effect is examined a) in genetically modified cultured cells or animal models (e.g., mouse or zebrafish (Yildiz et al., Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J Clin Invest. 2006 Nov;116(11):2985-94; Lelieveld et al., Role of β-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish. J Lipid Res. 2019 Nov;60(11):1851-1867)) that are GBA2 deficient as a result of this modification, or b) in cultured cells or animal models in the presence of chemical inhibitors of GBA2 (e.g. MZ31 / L-ido-AMO-DNM (Wennekes et al., Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J Med Chem. 2010 Jan 28;53(2):689-98; Marques et al., Reducing GBA2 Activity Ameliorates Neuropathology in Niemann-Pick Type C Mice. PLoS One. 2015 Aug 14;10(8):e0135889).
[0114] 2) To determine in vitro whether a compound is transformed by GBA2, the protocol previously described in Lelieveld et al. (2019), supra; and Marques et al., Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular beta-glucosidases. J Lipid Res. 2016 Mar;57(3):451-63 can be used. Briefly, human cell cultures expressing GBA2 (e.g., HeLa or HEK293T) are grown. For experiments, cells are harvested in phosphate-buffered saline (PBS), centrifuged, resuspended in 25 mM potassium phosphate buffer supplemented with 0.1% (v / v) Triton-X100 and benzonase (25 mM Kpi pH 6.5, 0.1% Triton-X100, 25 U / mL benzonase), and lysed by sonication. The cell homogenate is added to McIlvaine buffer of appropriate pH mixed with the compound and supplemented with additives (100 μL containing 1% ethanol, 3.75 mM 4MU-β-Glc, 0.1% (w / v) BSA and 25 μM cholesterol in 150 mM McIlvaine pH 4 or pH 5.2 supplemented with 0.1% (v / v) Triton-X100 and / or 0.2% (w / v) sodium taurocholate). After 1 h incubation at 37 °C with shaking, 5 μL of sample is transferred to 200 μL of STOP buffer (1 M glycine-NaOH, pH 10.3). Proteins are precipitated by the addition of methanol and chloroform (2:1 (v / v)) and after centrifugation, lipids in the supernatant are extracted by Bligh-Dyer extraction (MeOH:CHCl 3 :H 2 The extract is diluted with 100% ethanol and 1:1:0.9 (1:1:0.9) and measured using liquid chromatography / mass spectrometry (LC / MS).
[0115] Compositions and Administration According to a further aspect of the present invention, there is provided a pharmaceutical composition comprising the compound of the present invention. For example, the pharmaceutical composition may comprise any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc or formula Vd. The composition may be provided by mixing the compound with at least one pharma- ceutically acceptable adjuvant, carrier or diluent. The composition may be formulated for parenteral administration, particularly parenteral systemic administration. The composition may be formulated for parenteral administration. The composition may be formulated for injection, for example, for intravenous or intramuscular injection.
[0116] The compound or composition of the present invention may be administered orally, topically, intravenously, subcutaneously, buccal, rectal, transdermal, nasal, tracheal, bronchial, other parenteral routes, as an oral or nasal spray, or via inhalation.Preferably, the compound or composition is formulated for parenteral administration.The compound may be administered in the form of a pharmaceutical preparation that contains the compound in a pharmaceutical acceptable dosage form, either as a free compound or as an addition salt, for example, of a pharmaceutical acceptable non-toxic organic or inorganic acid or base.The composition may be administered in various doses, depending on the disorder and patient to be treated and the route of administration.
[0117] Parenteral forms of administration may be preferred because the carbohydrate moiety (e.g., monosaccharide or disaccharide) of the compounds of the invention may mask the activity of the remainder of the compounds of the disclosure. The carbohydrate moiety is removed to provide the active aglycosylated moiety. In parenteral administration, the removal of the carbohydrate moiety may occur at or near the site of inflammation (e.g., via GBA2-catalyzed hydrolysis). This provides the active compound at or near the site of inflammation, which is usually less active away from the site of inflammation, and can reduce side effects, especially when the compound is administered systemically. This advantage may be reduced when the compound is administered orally, since the carbohydrate moiety may be hydrolyzed by the gut microflora.
[0118] Thus, the pharmaceutical compounds of the present invention can be administered parenterally (as used herein, "parenterally" refers to modes of administration including intravenous, intramuscular, intraperitoneal, intrathoracic, subcutaneous and intraarticular injection and infusion) or orally to a host to obtain a therapeutic effect (such as an anti-inflammatory or chemotherapeutic effect). For example, the pharmaceutical compounds of the present invention can be administered by intravenous injection or infusion. In the case of large animals such as humans, the compounds of the present invention can be administered alone or as a composition in combination with a pharma- ceutical acceptable diluent, excipient or carrier.
[0119] The actual dosage levels of the active ingredients in the pharmaceutical formulations and compositions of the present invention may be varied to obtain an amount of the active compound effective to achieve the desired therapeutic response for a particular patient, composition and mode of administration. The selected dosage level will depend on the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and medical history of the patient being treated. However, it is within the skill of one of ordinary skill in the art to begin administration of the compound at a level lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. Suitable dosages are generally in the range of 0.01 to 100 mg / kg / day, for example, 0.1 to 50 mg / kg / day.
[0120] The pharmaceutical composition of the present invention for parenteral (e.g., intravenous) injection may comprise pharma- ceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions immediately before use. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils (e.g., olive oil), and injectable organic esters, such as ethyl oleate. The proper fluidity can be maintained, for example, by using coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by using surfactants. Parenteral injection compositions may represent the preferred compositions of the present invention.
[0121] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of microbial action can be ensured by including various antibacterial and antifungal agents, such as parabens, chlorobutanol or phenol sorbic acid. It may also be desirable to include isotonic agents, such as sugars or sodium chloride. Prolonged absorption of the injectable pharmaceutical form can be achieved by including agents that delay absorption, such as aluminum monostearate and gelatin.
[0122] Compositions for rectal or vaginal administration may be in the form of suppositories which can be prepared by mixing a compound of the present invention with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or a suppository wax which is solid at room temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity to release the active compound.
[0123] The topical administration dosage form of the compound of the present invention includes powder, spray, cream, foam, gel, ointment, inhalant, etc. The active compound is mixed under sterile conditions with a pharma- ceutically acceptable carrier and necessary preservatives, buffers or propellants. Ophthalmic preparations, eye ointments, powders and solutions are also considered to be within the scope of the present invention.
[0124] The compositions according to the present subject matter may contain inactive ingredients. Suitable inactive ingredients are well known in the art and are described in Goodman and Gillman: The Pharmacological Bases of Therapeutics, 13 th Ed., Brunton et al., Eds. McGraw-Hill Education (2017), and Remington's Pharmaceutical Sciences, 17 th Ed., Mack Publishing Co., Easton, Pa. (1990), both of which are incorporated herein by reference.
[0125] The composition can be used in combination with additional pharmaceutical dosage forms to improve the effectiveness in treating any of the disorders described herein.In this regard, the formulation can be administered as part of a regimen that additionally includes any other medicament and / or pharmaceutical dosage form known in the art to be effective in treating any of these disorders.
[0126] Purpose The compounds of the present invention represent novel mono- and disaccharide-containing derivatives of therapeutic moieties, such as anti-inflammatory and chemotherapeutic moieties, and are therefore useful in the treatment of inflammation and / or cancer.
[0127] We have established that therapeutic agents, such as anti-inflammatory or anti-cancer agents, can be converted into prodrugs by the addition of a mono- or disaccharide to provide compounds that include a glycan (mono- or disaccharide) moiety and a therapeutic (e.g., anti-inflammatory or chemotherapeutic) moiety.
[0128] GBA2, for example, GBA2 present at or near a site of inflammation, is believed to hydrolyze the carbohydrate moiety to provide the active aglycone form of the therapeutic (eg, anti-inflammatory or chemotherapeutic) moiety.
[0129] Inflammatory conditions are characterized by excessive and / or uncontrolled and / or chronic inflammation (collectively referred to herein as "hyperactivity" of the immune system). Inflammation is the body's response to harmful stimuli, such as pathogens, damaged cells or irritants. It is a general, non-specific response involving the immune system. It has five main symptoms: heat, pain, redness, swelling and loss of function. The function of inflammation is to expel pathogens or substances, damaged cells and tissues from the body and to initiate tissue repair. However, excessive (often chronic) inflammation is associated with many clinical problems. It can be uncomfortable, impede or delay the normal progression of the healing response, prolong injury, and result in a variety of diseases. These include autoimmune diseases resulting from abnormal immune responses to functional body parts, such as rheumatoid arthritis, allergies resulting from excessive responses to foreign (often harmless) substances, such as hay fever, atopic dermatitis and allergic asthma, and inflammation associated with infectious diseases, such as COVID-19 and tuberculosis.
[0130] Conditions characterized by the hyperproliferation of cells belonging to the immune system include leukemia - acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). ALL is a cancer of the lymphatic system of blood cells, characterized by the development of large numbers of immature lymphocytes, while AML is a cancer of the myeloid system of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and prevent the production of normal blood cells.
[0131] Moreover, it should be noted that already in the 19th century, cancer was recognized to be associated with inflammation (Balkwill et al., Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005 Mar;7(3):211-7; Mantovani et al., Cancer-related inflammation. Nature. 2008 Jul 24;454(7203):436-44; Multhoff et al., Chronic inflammation in cancer development. Front Immunol. 2012 Jan 12;2:98; Danforth, The Role of Chronic Inflammation in the Development of Breast Cancer. Cancers (Basel). 2021 Aug 3;13(15):3918). Inflammatory components are present in the microenvironment of most neoplastic tissues, including those independent of obvious inflammatory processes. A key feature of cancer-associated inflammation (CRI) includes the infiltration of leukocytes, particularly tumor-associated macrophages (TAMs (Kimm et al., Tumor-Associated Macrophages-Implications for Molecular Oncology and Imaging. Biomedicines. 2021 Apr 2;9(4):374), which are likely to express GBA2. Thus, without wishing to be bound by any theory, glycosylated prodrugs of chemotherapeutic agents that are substrates of GBA2 (such as the compounds disclosed herein, e.g., compounds of Formulas I and II) induce target activity in the tumor and its microenvironment, where they are locally converted to the more active (non-glycosylated) form. This may result in reduced side effects compared to direct administration of the corresponding non-glycosylated chemotherapeutic agent.
[0132] In one aspect of the present invention, there is provided a compound of the present invention or a pharmaceutical composition of the present invention for use as a medicament. The compound may be, for example, any of the compounds of formula I, II, IIIa, IIIb, IVa, IVb, Va, Vb, Vc or Vd. The composition may include any of the compounds of formula I, II, IIIa, IIIb, IVa, IVb, Va, Vb, Vc or Vd. Such applications may utilize the compounds of the present invention incorporating any suitable therapeutic moiety that is desired to be delivered to the site of inflammation. Advantageously, such applications may utilize the compounds of the present invention incorporating an anti-inflammatory moiety or a chemotherapeutic moiety.
[0133] Inflammation and / or inflammatory conditions that lead to the upregulation of GBA2 are associated with many pathologies. The compounds of the present invention and disclosure (e.g., any of the compounds of formula I, II, IIIa, IIIb, IVa, IVb, Va, Vb, Vc, or Vd) or pharmaceutical compositions containing such compounds can be used to treat such conditions or pathologies.
[0134] Although the compounds of the present invention are suitable for the delivery of anti-inflammatory agents, they may also be used for the targeted delivery of other therapeutic moieties to sites of inflammation. As inflammation is present in many pathological processes and conditions, a wide range of therapeutic moieties may be usefully targeted in this manner.
[0135] Since inflammation is known to be associated with infection, the compounds of the invention may include an anti-infective agent as a therapeutic moiety, and such compounds of the invention may be used as pharmaceuticals for the treatment of infections and / or complications of infections associated with inflammation.
[0136] Since pain is known to be associated with many processes involving inflammation, the compounds of the invention may contain an analgesic as a therapeutic moiety, and such compounds of the invention may be used as medicines to relieve pain, particularly pain associated with inflammation.
[0137] Inflammation is also known to be related to many processes in which excessive or pathological angiogenesis occurs.Therefore, the compounds of the present invention can include angiogenesis inhibitors as therapeutic moieties.Such compounds of the present invention can be used as pharmaceuticals for treating conditions associated with excessive angiogenesis.By way of example only, such conditions include cancer, psoriasis, vascular retinopathy (such as proliferative diabetic retinopathy or wet macular degeneration), and wound healing.
[0138] The role of inflammation in wound healing lends itself to medical applications of compounds of the invention that contain an anti-fibrotic agent as a therapeutic moiety, such compounds of the invention may be used as pharmaceuticals to inhibit scarring.
[0139] Accordingly, suitable therapeutic moieties that may be incorporated into the compounds of the invention are not limited to anti-inflammatory or chemotherapeutic moieties, but may also include, by way of example only, anti-fibrotic, analgesic, anti-angiogenic, or anti-infective moieties.
[0140] The use in any of the applications discussed above may include parenteral administration of the compound or composition to a patient. Parenteral administration may include parenteral administration. For example, parenteral administration may include injection.
[0141] In one aspect of the present invention, the compound of the present invention or the pharmaceutical composition of the present invention is provided for use in treating inflammation. This aspect also provides the compound of the present invention or the pharmaceutical composition of the present invention for use in reducing inflammation. The compound can be, for example, any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc, or formula Vd. The composition can include any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc, or formula Vd. In such applications, the compound of the present invention incorporating an anti-inflammatory moiety can be utilized.
[0142] The use may include parenteral administration of the compound or composition to a patient. Parenteral administration may include parenteral administration. For example, parenteral administration may include injection.
[0143] In another aspect of the present invention, a method for treating inflammation is provided, which comprises administering (e.g., parenterally) an effective amount of a compound of the present invention or a pharmaceutical composition of the present invention to a patient. The compound can be, for example, any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc, or formula Vd. The composition can include any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc, or formula Vd. In such applications, the compound of the present invention incorporating an anti-inflammatory moiety can be utilized.
[0144] In a related aspect, there is provided a use of a compound of the invention for the manufacture of a medicament for treating inflammation.
[0145] In one aspect of the present invention, the compound of the present invention or the pharmaceutical composition of the present invention is provided for use in treating inflammatory or other conditions characterized by hyperactivity of the immune system.The compound can be, for example, any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc or formula Vd.The composition can include any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc or formula Vd.In such applications, the compound of the present invention incorporating an anti-inflammatory moiety can be utilized.
[0146] The inflammatory or other condition may be selected from arthropathy, osteoarthropathy, gout, rheumatoid arthritis, other autoimmune disorders (e.g., systemic lupus erythematosus (SLE), inflammatory bowel disease (including IBD, Crohn's disease, ulcerative colitis), multiple sclerosis, chronic inflammatory demyelinating polyneuropathy (CIPD)), infectious diseases (e.g., COVID-19 and tuberculosis), asthma, chronic obstructive pulmonary disease (COPD), allergic and non-allergic rhinitis and sinusitis, tendonitis, nasal polyps, skin conditions (e.g., rash, dermatitis, pruritus, eczema, dermatomycoses, lichen sclerosus or rubra, and psoriasis), eye diseases (e.g., uveitis, conjunctivitis, macular edema), otitis, thyroiditis, sarcoidosis, myositis, vasculitis, hemorrhoids, organ rejection in transplant recipients, and graft-versus-host disease.
[0147] The inflammatory or other condition may be selected from rheumatoid arthritis, other autoimmune disorders (e.g., systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD)), thyroiditis, asthma, chronic obstructive pulmonary disease (COPD), allergic and non-allergic rhinitis, respiratory infections (e.g., COVID-19), nasal polyps, psoriasis, eczema, dermatitis, eye diseases, and graft-versus-host disease. The inflammatory or other condition may be selected from rheumatoid arthritis, other autoimmune disorders (e.g., systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD)), and thyroiditis.
[0148] The use may include parenteral administration of the compound or composition to a patient. Parenteral administration may include parenteral administration. For example, parenteral administration may include injection.
[0149] In another aspect of the present invention, a method for treating an inflammatory or other condition characterized by immune system hyperactivity is provided, comprising administering (e.g., parenterally) to a patient an effective amount of a compound of the present invention or a pharmaceutical composition of the present invention. The compound can be, for example, any of the compounds of formula I, II, IIIa, IIIb, IVa, IVb, Va, Vb, Vc, or Vd. The composition can include any of the compounds of formula I, II, IIIa, IIIb, IVa, IVb, Va, Vb, Vc, or Vd.
[0150] The inflammatory or other condition may be selected from arthropathy, osteoarthropathy, gout, rheumatoid arthritis, other autoimmune disorders (e.g., systemic lupus erythematosus (SLE), inflammatory bowel disease (including IBD, Crohn's disease, ulcerative colitis), multiple sclerosis, chronic inflammatory demyelinating polyneuropathy (CIPD)), infectious diseases (e.g., COVID-19 and tuberculosis), asthma, chronic obstructive pulmonary disease (COPD), allergic and non-allergic rhinitis and sinusitis, tendonitis, nasal polyps, skin conditions (e.g., rash, dermatitis, pruritus, eczema, dermatomycosis, lichen sclerosus or rubra, and psoriasis), eye diseases (e.g., uveitis, conjunctivitis, macular edema), otitis, thyroiditis, sarcoidosis, myositis, vasculitis, hemorrhoids, organ rejection in transplant recipients, and graft-versus-host disease.
[0151] The inflammatory or other condition may be selected from rheumatoid arthritis, other autoimmune disorders (e.g., systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD)), thyroiditis, asthma, chronic obstructive pulmonary disease (COPD), allergic and non-allergic rhinitis, respiratory infections (e.g., COVID-19), nasal polyps, psoriasis, eczema, dermatitis, eye diseases, and graft-versus-host disease. The inflammatory or other condition may be selected from rheumatoid arthritis, other autoimmune disorders (e.g., systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD)), and thyroiditis.
[0152] In a related aspect, there is provided the use of a compound of the invention for the manufacture of a medicament for the treatment of an inflammatory or other condition characterized by immune system hyperactivity, as further defined above.
[0153] In one aspect of the present invention, the compound of the present invention or the pharmaceutical composition of the present invention is provided for use in treating a condition characterized by the hyperproliferation of cells belonging to the immune system.The compound can be, for example, any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc or formula Vd.The composition can include any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc or formula Vd.In such applications, the compound of the present invention incorporating a chemotherapeutic moiety can be utilized.
[0154] The condition may be selected from acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
[0155] The use may include parenteral administration of the compound or composition to a patient. Parenteral administration may include parenteral administration. For example, parenteral administration may include injection.
[0156] In another aspect of the present invention, a method for treating a condition characterized by hyperproliferation of cells belonging to the immune system is provided, which comprises administering (e.g., parenterally) an effective amount of a compound of the present invention or a pharmaceutical composition of the present invention to a patient. The compound can be, for example, any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc, or formula Vd. The composition can include any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc, or formula Vd. In such applications, the compounds of the present invention incorporating a chemotherapeutic moiety can be utilized.
[0157] The condition may be selected from acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
[0158] In a related aspect, there is provided a use of a compound of the invention for the manufacture of a medicament for treating a condition characterized by hyperproliferation of cells belonging to the immune system, which may be as further defined above.
[0159] In one aspect of the present invention, the compound of the present invention or the pharmaceutical composition of the present invention is provided for use in the treatment of cancer.Cancer can be selected from acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).The compound can be, for example, any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc or formula Vd.The composition can include any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc or formula Vd.In such applications, the compound of the present invention incorporating a chemotherapeutic moiety can be utilized.
[0160] The use may include parenteral administration of the compound or composition to a patient. Parenteral administration may include parenteral administration. For example, parenteral administration may include injection.
[0161] In another aspect of the present invention, a method of treating cancer is provided, comprising administering (e.g., parenterally) an effective amount of a compound of the present invention or a pharmaceutical composition of the present invention to a patient. The cancer may be selected from acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The compound may be, for example, any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc, or formula Vd. The composition may include any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc, or formula Vd. In such applications, the compounds of the present invention incorporating a chemotherapeutic moiety may be utilized.
[0162] In a related embodiment, the use of the compound of the present invention for the manufacture of a medicament for treating cancer is provided.Cancer can be selected from acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).The compound can be, for example, any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc, or formula Vd.The composition can include any of the compounds of formula I, formula II, formula IIIa, formula IIIb, formula IVa, formula IVb, formula Va, formula Vb, formula Vc, or formula Vd.In such applications, the compound of the present invention incorporating a chemotherapeutic moiety can be utilized.
[0163] In one aspect of the present invention, the use of the compound of the present invention as an anti-inflammatory agent is provided.The use comprises contacting the compound with cells expressing glucosylceramidase beta 2 (GBA2).In such applications, the compound of the present invention incorporating an anti-inflammatory moiety can be utilized.
[0164] The use may be in vitro. The cell may be in a tissue or organ. The cell may be in a cell culture. The compound may be any of the compounds of formula I, II, IIIa, IIIb, IVa, IVb, Va, Vb, Vc, or Vd. The composition may include any of the compounds of formula I, II, IIIa, IIIb, IVa, IVb, Va, Vb, Vc, or Vd.
[0165] Assay The compounds of the present invention can be evaluated for biological activity using any suitable assay that would be known to one of skill in the art. Exemplary assays useful for evaluating the compounds of the present invention are provided in the following paragraphs.
[0166] material and method Zebrafish (Danio rerio) were kept and handled according to the guidelines of the Zebrafish Model Organism Database (https: / / zfin.org / ) and in accordance with the instructions of the local animal welfare committee at the University of Leiden. To maintain circadian rhythmicity, adult fish were exposed to a cycle of 14 h light and 10 h dark. Fertilization occurred by natural spawning at the beginning of the light period. Fertilized eggs were collected and kept in egg water (60 μg / ml Instant Ocean sea salt and 0.0025% methylene blue) at 28 °C. The following zebrafish strains were used in this study: AB / TL wild type, transgenic line Tg(mpx:GFP i114 / mpeg1:mCherry umsF001 )(Bernut et al., (2014). Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation. Proc Natl Acad Sci USA 111, E943-952; Renshaw et al., (2006). A transgenic zebrafish model of neutrophilic inflammation. Blood 108, 3976-3978), and Tg(9xGCRE-HSV.UI23:EGFP) ia20 (Benato et al., (2014). A living biosensor model to dynamically trace glucocorticoid transcriptional activity during development and adult life in zebrafish. Mol Cell Endocrinol 392, 60-72), mutant strain gba2 - / -(Lelieveld et al., (2019). Role of beta-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish. J Lipid Res 60, 1851-1867), and gr s357 (Ziv et al., (2013). An affective disorder in zebrafish with mutation of the glucocorticoid receptor. Mol Psychiatry 18, 681-691).
[0167] The compounds beclomethasone, prednisolone, dexamethasone, PPD, Rb1, F2 and miglustat were purchased from Sigma-Aldrich (Burlington, MA, USA), dexamethasone-glucuronide (referred to as glucuronidated dexamethasone, GDex) was purchased from Santa Cruz (Dallas, TX, USA), ME656 and MZ31 were kindly provided by Dr. Hans Aerts (Leiden University, The Netherlands). The compounds 21-O-Glc-prednisolone (glucosidized prednisolone, GPdn) and 21-O-Gb-prednisolone (gentiobioside-prednisolone, GbPdn) were synthesized as described in the Examples herein.
[0168] Tail fin amputation assay In the tail fin amputation experiment, Tg(mpx:GFP i114 / mpeg1:mCherry umsF001Three-day-post-fertilization (dpf) larvae of the ) strain were anesthetized with 0.02% buffered aminobenzoic acid ethyl ester (tricaine) in egg water and placed on 2% agarose-coated Petri dishes. The tail was partially amputated with a 1 mm sapphire blade (World Precision Instruments) under a Leica M165C stereomicroscope (Leica Microsystems, Wetzlar, Germany). Chemical treatments (or 0.1% DMSO as vehicle treatment) began 2 h before amputation (pretreatment) and continued for 4 h after caudal fin amputation (20 larvae per group unless otherwise stated), at which point larvae were fixed overnight in 4% paraformaldehyde (PFA) at 4°C and stored at 4°C until further examination. In some experiments, 24-h treatments with miglustat, ME656 or MZ31 were started at 2 dpf and these treatments continued during pretreatment and treatment with other chemicals. Tg(mpx:GFP i114 / mpeg1:mCherry umsF001 A Leica MZ16FA fluorescence stereomicroscope equipped with LAS 3.7 software was used to image larvae from the gba2 lineage. Neutrophils were detected by GFP fluorescence and macrophages by mCherry fluorescence. The number of neutrophils was determined by blinded manual counting in predefined areas. - / - or gr s357 When mutant strain larvae were used, neutrophils were labeled using a TSA Fluorescein Detection Kit (PerkinElmer) for specific staining of myeloperoxidase (Mpx) positive cells according to the manufacturer's instructions.
[0169] Measurement of larval body length and caudal fin regeneration To read the regeneration of the caudal fin after wounding or the body length of the larvae, chemical treatment of embryos was started 2 hours post-fertilization (hpf) and continued until 5 dpf. During this time, the solution was refreshed daily. At 5 dpf, larvae were imaged with a Leica MZ16FA fluorescence stereo microscope (compatible with LAS 3.7 software) and the body length of the larvae was measured using ImageJ software (15 per treatment group). For the regeneration experiment, the caudal fin was amputated at 2 dpf and the larvae were imaged at 5 dpf (15 per treatment group). The newly grown tissues could be distinguished from the old tissues, so the size of the newly grown tissues could be accurately measured using ImageJ software.
[0170] Whole-body glucose measurement using a colorimetric assay Zebrafish embryos at 2 hpf were subjected to the indicated chemical treatments, with solutions refreshed daily, until 5 dpf. At 5 dpf, larvae were collected in Eppendorf tubes and 100 μL of ice-cold glucose buffer was added to each sample. Larvae were homogenized at 8,000 rpm for 3 min using a BulletBlender®. The homogenates were then centrifuged at 11000 rpm for 8 min at 4°C and the supernatants were stored at -20°C. Whole-body glucose concentrations were measured using a glucose colorimetric assay kit (Cayman Chemical, USA) according to the manufacturer's instructions. In each experiment, three biological replicates were used for each treatment group, and colorimetric measurements were performed using technical duplicates.
[0171] Whole-body cortisol measurement using ELISA Zebrafish embryos at 2 hpf were subjected to the indicated chemical treatments, with solutions refreshed daily, until 96 hpf. Treatments were then discontinued and embryos were cultured in egg water until 5 dpf to avoid cross-reactivity with the compounds of the cortisol antibody used in the ELISA. Treatments were then discontinued and replaced with egg water. At 5 dpf, larvae were collected in Eppendorf tubes and 100 μL of ice-cold phosphate-buffered saline (PBS) was added. Larvae were homogenized for 3 min at 8,000 rpm using a BulletBlender®. Ethyl acetate was added to the homogenate and the supernatants were combined and evaporated. 150 μl of 0.2% bovine serum albumin (Sigma Aldrich) in phosphate-buffered saline (PBS) was added to the samples and frozen. Whole-body cortisol in zebrafish larvae was measured by ELISA (Demeditec Diagnostics GmbH, Kiel-Wellsee, Germany) according to the manufacturer's instructions. In each experiment, three biological replicates were used for each treatment group, and colorimetric measurements were performed using technical duplicates.
[0172] Transactivation activity of Gr in zebrafish reporter lines Tg(9xGCRE-HSV.UI23:EGFP) ia20 The zebrafish reporter line expresses enhanced green fluorescent protein (EGFP) under the control of a promoter containing an array of nine GREs. To examine the effect of chemical treatments on the transactivation activity of Gr, 15 zebrafish embryos (2 dpf) per group were treated with the indicated compounds for 24 h. The transactivation activity of Gr induced by the treatments was assessed using a Leica MZ16FA fluorescence stereomicroscope (compatible with LAS 3.7 software). The integrated intensity of the EGFP signal in larvae was measured using ImageJ software.
[0173] Overexpression of gba2 in zebrafish For overexpression of gba2 in zebrafish, we used a plasmid (pDEST-zeo-zGBA2 (Lelieveld et al., 2020) containing a cDNA encoding the zebrafish gba2 gene fused to the CMV promoter. One-cell stage zebrafish embryos were injected with this plasmid diluted in nuclease-free water (1 nl / egg, final concentration 80 pg / egg) using an Automated Microinjection System Version 3 AMS-03 (Life Science Methods BV). After injection, chemical treatments were performed as indicated.
[0174] Quantitative PCR (qPCR) analysis For experiments in zebrafish, gene expression was measured using 3 dpf embryos. Groups of 15 larvae were collected in TRIzol reagent (Invitrogen) and mRNA was isolated using the miRNeasy mini kit (Qiagen) according to the manufacturer's instructions. For experiments in HeLa cells, samples were taken from one well of a 6-well plate (80% confluent) in TRIzol reagent and mRNA was isolated using the RNeasy mini kit. Zebrafish and cell samples were stored in DNA-free TMThe RNA was treated with DNAse using a kit (Ambion). cDNA synthesis was performed using 1 μg of RNA per sample using the iScript cDNA synthesis kit (Bio-Rad). For qPCR, 10 μM forward primer and 10 μM reverse primer, 12.5 μL of iQ SYBR Green Supermix (Bio-Rad), and 2 μL of cDNA were added to the qPCR reaction mixture. The total volume of each mixture was 25 μL, which was divided into two volumes of 12.5 μL. The qPCR reaction was performed using a MyiQ-single-color real-time PCR detection system (Bio-Rad) with an initial denaturation of 95°C for 3 min, followed by 40 cycles of 95.5°C for 15 s, 60°C for 15 s, and 72°C for 30 s. The cycle threshold (Ct value, i.e., the cycle number at which the fluorescence intensity reached the threshold) was determined for each sample. Gene expression levels for each sample were normalized using expression of ppial (peptidyl prolyl isomerase Ab (cyclophilin A)) for zebrafish samples and 18S rRNA for human cells. Fold changes per sample (compared to respective control groups) were calculated using the ΔΔCt method. For each experiment, three biological triplicates were performed for each treatment group, and reactions were performed in duplicate.
[0175] Cell culture, transfection and shRNA gene knockdown HeLa cells (purchased from ATCC) were cultured in phenol red-free Dulbecco's Modified Eagle's Medium (DMEM) high glucose (HG) medium supplemented with 10% fetal calf serum (FCS) and 10% Glutamax (Sigma-Aldrich). Cells were maintained at 37°C and 5% CO 2 Cells were seeded in 6-well plates and allowed to adhere 24-48 hours prior to treatment. After adhesion, cells that reached 80% confluence were treated with the indicated chemicals (or 0.01% DMSO as vehicle) for 6 hours.
[0176] For overexpression of GBA2 in HeLa cells, a plasmid (pDEST-zeo-hGBA2 (Lelieveld et al., 2020)) containing cDNA encoding the human GBA2 gene fused to the CMV promoter was transfected into approximately 70% confluent HeLa cells. The plasmid was mixed with FuGENE HD transfection reagent (Promega, Madison, WI, USA) and 500 μl of serum-free DMEM. The mixture was incubated at room temperature for 20 min and added to HeLa cells cultured in supplemented DMEM. After 2 days, the medium was replaced and the indicated chemical treatments were performed for 6 h.
[0177] To knock down GBA1 and GBA2, lentiviral particles containing shRNAs against GBA1 and GBA2 were generated. For this purpose, plasmids developed by the RNAi Consortium containing shRNAs against GBA1 (TRCN0000029294) and GBA2 (TRCN0000049585) were used. These plasmids were mixed with a packaging plasmid (psPAX2) and a lentiviral envelope vector (pMD2.G) in 30 μl of transfection reagent (Lipo293D). This mixture was incubated for 20 min at room temperature and added to HEK293T Lenti-X cells cultured in complete DMEM medium. After 6 h, the medium was replaced with complete DMEM containing 25 mM HEPES. After 24 h, the cells were washed twice with PBS, the medium was replaced with fresh DMEM containing HEPES, and the lentiviral particles were collected after 48 and 72 h. The medium from the flasks was collected in a 50 ml sterile Falcon tube and centrifuged at 3,000 rpm for 7 min. The supernatant was filtered through a 0.45 μm filter. A titration was performed to determine the optimal viral dose required for efficient knockdown. Based on these experiments, an aliquot (2 ml) of lentivirus was added to 3 ml of serum-free DMEM containing 10 μg / ml polybrene. This mixture was added to HeLa cells cultured in fresh serum-supplemented DMEM at 70–80% confluence in a T75 flask. The medium was changed after 12–16 h, and cells were seeded in 6-well plates 48 h later. Chemical treatments were then performed as indicated for 6 h, and cells were harvested and qPCR analysis was performed to confirm knockdown of GBA1 and GBA2.
[0178] Activity-based probe assays Activity-based probe (ABP) assays were performed as previously described by Lelieveld et al., (2019). For experiments with zebrafish, 5 dpf larvae (10 per sample) were amputated and euthanized with 0.02% Tricaine on ice 4 h after amputation. Excess water was removed, 50 μL of homogenization buffer (25 mM KPI, pH 6.5, 0.1% v / v Triton-X) was added, homogenized by sonication on ice, and stored at -20 °C. In addition, to measure enzyme activity at the inflammatory site, larvae were amputated 4 h after amputation into parts anterior and posterior to the yolk extension and harvested separately (30 per sample). For experiments with HeLa cells, cells were grown to 80–90% confluence and treated with vehicle (0.001% DMSO) or TNF-α for 6 h. Homogenization buffer (25 mM KPI, pH 6.5, 0.1% v / v Triton-X) was added and samples were sonicated on ice and stored at -20°C.
[0179] β-Glucosidase probe (JJB367-Alkyl Cy5) in DMSO was diluted in McIlvaine buffer (citric acid / dibasic sodium phosphate: 100 mM / 200 mM mixture, pH 5.8) and 10 μL was added to 10 μl of protein sample (final probe concentration 10 μM in 1% DMSO) and incubated at 37 °C for 30 min. Laemmli sample buffer was added (15 μL) and the sample was incubated at 95 °C for 5 min. It was then immediately loaded onto a 12% SDS-PAGE gel (Bio-Rad Laboratories). The gel was run at 90 V for approximately 2 h and analyzed using a Typhoon FLA 9000 Gel Imager (GE Healthcare; Cy5 (λEX: 635 nm, λEM: 665 nm), 750 V, pixel size 100 μm). The intensity of the protein bands was quantified using ImageJ software. In each experiment, four biological replicates were used, except for the experiment in which larvae were divided into anterior and posterior sections, in which two biological replicates were used. Total protein concentrations of samples were quantified using a Bradford assay kit (Bio-Rad), allowing standardization of total protein concentrations.
[0180] Enzyme activity assay Zebrafish larvae were amputated at 5 dpf, euthanized with 0.02% tricaine on ice 4 h after amputation, and collected in Eppendorf tubes (10 larvae per sample). All excess water was removed, 50 μL of homogenization buffer (25 mM KPI, pH 6.5, 0.1% Triton-X) was added, and samples were homogenized by sonication on ice and stored at -20°C. Of the homogenates, 12.5 μL (corresponding to approximately one larva) was added to a black flat-bottom 96-well plate on ice along with 12.5 μL of Milli-Q water containing 5% DMSO (with or without GBA1 or GBA2 inhibitors). GBA1 inhibitor (ME656) solution was prepared at a final concentration of 1 μM. GBA2 inhibitor (MZ31) was used at a final concentration of 100 nM. The plate was incubated at 37°C for 30 min to allow the inhibitor to bind to the enzyme. 100 μL of 4MU (4-methylumbelliferyl-β-D-glucopyranoside) in 150 mM McIlvaine buffer, pH 5.8 was added. A blank contained 12.5 μL of homogenate, 12.5 μL Milli-Q with 5% DMSO, and 100 μL of 150 mM McIlvaine buffer, pH 5.8. The plate was briefly shaken and then incubated at 37°C for 2 h. After the incubation period, the plate was placed on ice and 200 μL of STOP buffer (1 M NaOH-glycine, pH 10.3) was added to each well. After the reaction was stopped, 4MU standards were made (10 μL of known 4MU standard (1 nmol), 15 μL of KPI buffer, 100 μL of 150 mM McIlvaine (pH 5.8), and 200 μL of STOP buffer) and added to another well. Then, a blank for 4MU standard (10 μL of Milli-Q, 15 μL of KPI buffer, 100 μL of 150 mM McIlvaine (pH 5.8), and 200 μL of STOP buffer) was prepared and added to another well. Then, the fluorescence intensity in all wells was measured using a fluorescence spectrometer LS-55 (PerkinElmer). Three biological replicates were used. The specific activity was calculated according to the following formula:
number
[0181] Competitor binding assay To measure the relative GR binding affinity of various compounds, PolarScreen TM A glucocorticoid receptor competitor assay kit (ThermoFisher) was used according to the manufacturer's instructions. Briefly, test compounds were first dissolved in DMSO to a stock concentration of 10 mM (100x) and further diluted in GR buffer (100 mM potassium phosphate (pH 7.4), 200 mM Na2MoO4, 1 mM EDTA, 20% DMSO). Serial dilutions of compounds were transferred to a Corning® black 384-well plate and stained with Fluormone GS red. TM was added, followed by GR Full Length (partially purified receptor in storage buffer). Plates were incubated at RT in the dark for 4 h and fluorescence polarization was measured using a CLARIOStar microplate reader (BMG Labtech). Values were normalized to the assay maximum (no ligand) and minimum controls (10 μM dexamethasone) to determine the relative percentage of polarization. Dose-response curves were fitted and IC50s values for each compound were calculated. Experiments were performed in duplicate.
[0182] Arthritis induction assay The efficacy of the compounds in treating inflammatory diseases can be examined using the collagen antibody-induced arthritis (CAIA) model in mice. The method is described below for the compound GbPdn, but one of skill in the art will readily understand how to generalize this to any related compound.
[0183] Male BALB / cAnNCrl mice (±8 weeks old) were purchased from Charles River. They were housed in individually ventilated cages with 4–5 mice per cage under specific pathogen-free (SPF) conditions. The experiments were reviewed by the animal welfare body of the LUMC and were carried out under a license granted by the Central Authority for Scientific Procedures on Animals under license and study number AVD11600202115391 / PE.15391.01.002, in accordance with the Dutch Animal Experiments Act and the EU Directive 2010 / 63 / EU.
[0184] All mice were administered 1.5 mg of CAIA-cocktail (Chondrex) intravenously on day 1, followed by an intraperitoneal (ip) injection of 50 μg LPS (Chondrex) on day 4. Mice were randomly divided into six groups. Each group contained four mice, except for the 25 mg / kg Pdn and GbPdn groups, which contained five mice per group. Pdn and GbPdn were diluted in 10% EtOH (vehicle) and administered daily by ip injection from day 7 to day 15 at doses of 12.5 mg / kg and 25 mg / kg for Pdn and 12.5 mg / kg, 25 mg / kg, and 50 mg / kg for GbPdn. Arthritis was scored daily from day 5 to day 15 as described by Jansen et al. (Jansen DT et al. Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model. Arthritis Res Ther 2015; 17: 220). Scores were assigned in a blinded manner. Blood was collected by tail vein sampling on days 0 (75 μl), 10 (40 μl), 14 (40 μl) and 15 (75 μl). Blood on day 14 was collected after a 6-h fast. Mice were sacrificed with carbon dioxide on day 15 and tissue samples were collected and immediately frozen in liquid nitrogen. Humane endpoints were weight loss of more than 20% compared to the day of LPS administration or an arthritis score of 45 points.
[0185] IL-6 concentrations were measured by ELISA in serum collected on days 10 and 15 using an IL-6 Mouse ELISA Kit (Invitrogen) according to the manufacturer's protocol. Insulin concentrations were measured in serum collected on day 14 using an Ultra-Ultrasensitive Mouse Insulin ELISA Kit (Crystal Chem) according to the manufacturer's protocol. Corticosterone concentrations were measured in serum collected on day 15 using a Corticosterone HS (High Sensitivity) Enzyme Immunoassay Kit (Immunodiagnostic Systems) according to the manufacturer's protocol. Expression levels of various GR target genes were measured by qPCR in tissue samples collected on day 15 (homogenized with TRIzol Reagent (ThermoFisher)).
[0186] Cleavage confirmation assay by liquid chromatography / mass spectrometry The ability of GBA2 to cleave sugars from compounds can be assessed by the following assay performed in zebrafish with liquid chromatography / mass spectrometry used to evaluate the resulting products. In the following method, compound GPdn is used along with appropriate standards of Pdn and GPdn. This method can be adapted to other glycosylated compounds by choosing appropriate standards to generate LC / MS calibration curves.
[0187] One hundred wild-type zebrafish larvae (with or without the Gba2 inhibitor MZ31) or gba2- / - larvae were wounded in the tail and treated with GbPdn for 6 h (2 h before wounding and 4 h after wounding) at 5 dpf. In the group treated with MZ31, the compound was added 24 h before wounding. Samples were collected with a cell strainer and quickly washed three times with MilliQ water to remove residual treatment solution. The washed larvae were immediately transferred to a 2 ml Eppendorf tube immersed in liquid nitrogen. The larvae were freeze-dried overnight and then homogenized with glass beads (5 mm) at 30 Hz for 2 min. The powdered fuchu was sonicated in 1 ml of 80% methanol for 20 min. The mixture was filtered through a 0.22 μm RC membrane.
[0188] To perform LC / MS, calibration curves were made using 2.5 pg / ml, 5 pg / ml, 25 pg / ml, 100 pg / ml, 500 pg / ml, 1000 pg / ml, and 5000 pg / ml of prednisolone, 21-glucose prednisolone, and 21-gentiobiose prednisolone spiked into blank samples (from untreated larvae). Compounds were analyzed on a Shimadzu LC-30AD (Japan) connected to a SCIEX Q-Trap 6500+ (Framingham, MA, USA) using an Acquity BEH C18 column (50 × 2.1 mm, 1.7 μm (Waters, USA)). The separation was performed at 40 °C, with a flow rate of 0.5 ml / min, for 3 min, with 25% B and 1% C, using three mobile phases: (A) water with 0.1% acetic acid, (B) ACN:methanol (9:1, v / v) with 0.1% acetic acid, and (C) isopropanol with 0.1% acetic acid. Multiple reaction monitoring (MRM) was utilized for MS / MS acquisition in positive electrospray ionization mode with a spray voltage of 4.5 kV, a capillary temperature of 600 °C, sheath gas 50, auxiliary gas 50, curtain gas 40, and collision energy of 20 V. Data were acquired using Sciex Analyst software (version 1.7, Framingham, MA, USA), and peak integration was performed using Sciex OS (version 1.4.0, Framingham, MA, USA). EXAMPLES
[0189] In the synthetic examples (Examples 1 and 2), all reagents used were of American Chemical Society (ACS) grade or higher and were used without further purification unless otherwise stated. NMR characterization was performed using a Bruker 500 (500 MHz) with DMSO-d6. HRMS analysis was performed on a Shimadzu Nexera X2 UHPLC system equipped with a diode array detector using a Waters Acquity HSS C18 column (2.1 x 100 mm, 1.8 μm) at 30°C. The following solvent systems were used at a flow rate of 0.5 mL / min: Solvent A, 0.1% formic acid in water; Solvent B, 0.1% formic acid in acetonitrile. Gradient elution was performed as follows: 95:5 (A / B) in 1 min, 95:5 to 15:85 (A / B) over 6 min, split 15:85 to 0:100 (A / B) in 1 min, 0:100 (A / B) for 3 min, then back to 95:5 (A / B) in 3 min. The system was interfaced to a Shimadzu 9030 QTOF mass spectrometer (ESI ionization) internally calibrated with an Agilent API-TOF Reference Mass Solution Kit (5.0 mM purine, 100.0 mM ammonium trifluoroacetate, and 2.5 mM hexakis(1H,1H,3H-tetrafluoropropoxy)phosphazene) diluted to achieve a mass count of 10,000. Preparative HPLC was performed on a BESTA-Technik system equipped with a Dr. Maisch Reprosil Gold 120 C18 column (25×250 mm, 10 μm) and an ECOM flash UV detector monitored at X nm. The following solvent system was used at a flow rate of 12 mL / min: Solvent A, 0.1% TFA in water / acetonitrile 95 / 5; Solvent B, 0.1% TFA in water / acetonitrile 5 / 95. Gradient elution was performed as follows: 95:5 (A / B) for 2 min, 95:5 to 0:100 (A / B) for 55 min, 0:100 (A / B) for 2 min, then 95:5 (A / B) for 1 min, then back to 95:5 (A / B) for 2 min.
[0190] While the examples and reaction schemes provided illustrate the synthesis of particular glycosylated corticosteroids, as one of skill in the art would understand, these methods can be generalized to synthesize other glycosylated corticosteroids, e.g., using different sugars and / or different corticosteroids.
[0191] Example 1: Synthesis of 21-O-glucose-prednisolone [ka]
[0192] 21-O-Glucose-Prednisolone was prepared according to Reaction Scheme 1. Under an argon atmosphere, prednisolone (0.50 g, 1.39 mmol), silver triflate (1.1 eq, 0.39 g, 1.53 mmol), and ground 4 Å molecular sieves (1.2 g) were stirred in 10 ml of DCM at room temperature for 1 h. The reaction mixture was cooled to 0° C., and bromo-α-D-glucose tetraacetate (1.1 eq, 0.63 g, 1.53 mmol) in 10 ml of DCM was added dropwise over 1 h. After stirring the reaction mixture at 0° C. for 1 h, the ice-water bath was removed and the mixture was stirred at room temperature overnight. The next day, the reaction mixture was filtered through Celite, and a saturated solution of sodium bicarbonate was added to the filtrate. After 2.5 h, the organic and aqueous phases were separated. The organic phase was then washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The mixture was then applied to a silica column and eluted with a gradient from 100% DCM to 70:30 DCM / acetone to obtain a partially purified intermediate product deemed suitable for the subsequent deprotection step. The peracetylated glucose-prednisolone conjugate was then dissolved in 3 ml of anhydrous methanol, and 1.5 ml of anhydrous chloroform and 0.32 ml of 25% wt sodium methoxide in methanol were added dropwise under argon atmosphere. After stirring for 1 h, the mixture was neutralized by adding Dowex 50WX8(H+) resin. The resin was then removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified using RP-HPLC and lyophilized to give 125 mg of 21-O-Glc-Prednisolone as a fluffy white powder in 17% yield over two steps. [M+H]+ calculated for C27H38O10, 523,2538 (HRMS) 523,2538.
[0193] 1H NMR (500 MHz, DMSO) δ 7.32 (d, J = 10.1 Hz, 1H), 6.16 (dd, J = 10.1, 1.9 Hz, 1H), 5.91 (t, J = 1.6 Hz, 1H), 5.28 (s, 1H), 4.78 (d, J = 18.2 Hz, 1H), 4.59 (s, 1H), 4.34 (d, J = 18.2 Hz, 1H), 4.30 - 4.23 (m, 1H), 4.17 (d, J = 7.8 Hz, 1H), 3.69 (dd, J = 11.8, 2.0 Hz, 2H), 3.49 - 3.37 (m, 1H), 3.16 - 3.07 (m, 2H), 3.06 - 2.97 (m, 2H), 2.58 - 2.51 (m, 2H), 2.33 - 2.22 (m, 1H), 2.11 - 1.94 (m, 3H), 1.87 (dd, J = 13.7, 3.6 Hz, 1H), 1.70 - 1.57 (m, 4H), 1.44 - 1.35 (m, 5H), 1.34 - 1.22 (m, 1H), 1.01 (qd, J = 13.2, 4.6 Hz, 1H), 0.89 (dd, J = 11.0, 3.5 Hz, 1H), 0.78 (s, 3H).
[0194] 13 C NMR (126 MHz, DMSO) δ 208.53, 185.70, 171.05, 157.26, 127.61, 121.72, 102.41, 89.25, 77.53, 77.19, 73.85, 71.69, 70.53, 69.03, 61.61, 55.85, 51.58, 47.19, 44.31, 40.56, 40.39, 40.23, 40.06, 39.89, 39.73, 39.56, 39.43, 34.50, 33.24, 31.86, 31.51, 24.08, 21.37, 17.45.
[0195] Example 2: Synthesis of 21-O-ゲンチオビオース-プレドニゾロンの
change
[0196] 21-O-gentiobiose-prednisolone was prepared according to reaction scheme 2. Under an argon atmosphere, prednisolone (0.50 g, 1.39 mmol), silver triflate (1.1 eq, 0.39 g, 1.53 mmol), and ground 4 Å molecular sieves (1.2 g) were stirred in 10 ml of DCM at room temperature. The reaction mixture was cooled to 0 °C and bromo-α-D-gentiobiose octaacetate (1.1 eq, 1.10 g, 1.53 mmol) in 10 ml of DCM was added dropwise for 1 h. After stirring the reaction mixture at 0 °C for 1 h, the ice-water bath was removed and the mixture was stirred at room temperature overnight. The next day, the reaction mixture was filtered through Celite and a saturated solution of sodium bicarbonate was added to the filtrate. After 2.5 h, the organic and aqueous phases were separated. The organic phase was then washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The mixture was applied to a silica column and eluted with a gradient of 100% DCM to 70:30 DCM / acetone to give a partially purified intermediate product deemed suitable for the subsequent deprotection step. The peracetylated gentiobiose-prednisolone conjugate was dissolved in 3 ml of anhydrous methanol, then 1.5 ml of anhydrous chloroform and 0.32 ml of 25% wt sodium methoxide in methanol were added dropwise under an argon atmosphere. After stirring for 1 h, the mixture was separated using Dowex 50WX8 (H + ) resin was added to neutralize the mixture. The resin was then removed by filtration and concentrated under reduced pressure. The residue was purified using RP-HPLC and lyophilized to give 221 mg of 21-O-gentiobiose-prednisolone as a fluffy white powder in 23% yield over two steps. 33 H 48 O 15 , 685,3066 calculated [M+H] + was (HRMS) 685,3067.
[0197] 1H NMR (500 MHz, DMSO) δ 7.33 (d, J = 10.1 Hz, 1H), 6.15 (dd, J = 10.0, 1.9 Hz, 1H), 5.91 (t, 1H), 5.24 (s, 1H), 4.83 (d, J = 18.3 Hz, 1H), 4.61 (s, 1H), 4.33 (s, 1H), 4.29 (s, 1H), 4.19 (dd, J = 10.1, 7.8 Hz, 2H), 3.96 (dd, J = 11.5, 1.9 Hz, 1H), 3.66 (dd, J = 11.8, 1.7 Hz, 1H), 3.58 (dd, J = 11.4, 5.9 Hz, 1H), 3.44 (dd, J = 11.6, 5.2 Hz, 1H), 3.34 - 3.27 (m, 1H), 3.18 - 3.10 (m, 3H), 3.08 - 3.01 (m, 3H), 2.99 - 2.94 (m, 1H), 2.56 - 2.51 (m, 2H), 2.32 - 2.25 (m, 1H), 2.07 - 1.97 (m, 2H), 1.86 (dd, J = 13.8, 3.7 Hz, 1H), 1.73 - 1.52 (m, 2H), 1.45 - 1.33 (m, 4H), 1.28 (dd, J = 11.4, 6.3 Hz, 1H), 0.99 (qd, J = 13.1, 4.6 Hz, 1H), 0.88 (m, 1H), 0.78 (s, 3H).
[0198] 13C NMR (126 MHz, DMSO) δ 208.54, 185.75, 171.12, 157.37, 127.58, 122.09, 103.86, 102.78, 89.19, 77.39, 77.22, 77.07, 76.08, 74.00, 73.74, 72.27, 70.56, 70.12, 68.97, 68.74, 61.53, 55.85, 47.28, 47.25, 44.32, 40.51, 40.34, 40.17, 40.00, 39.84, 39.67, 39.50, 39.45, 34.50, 33.36, 31.87, 31.48, 24.05, 21.38, 17.45.
[0199] Example 3: Anti-inflammatory effect of ginsenosides It has been previously reported that ginsenosides have anti-inflammatory effects via activation of GR (He et al., 2020, Ginsenoside Rg1 Acts as a Selective Glucocorticoid Receptor Agonist with Anti-Inflammatory Action without Affecting Tissue Regeneration in Zebrafish Larvae. Cells 9). To study this effect in more detail, we induced a local inflammatory response in zebrafish larvae by wounding the caudal fin (Figure 1A), which resulted in migration of leukocytes toward the wound site and increased expression of pro-inflammatory genes (Renshaw et al., 2006, Blood 108, 3976-3978; Xie et al., 2019, Dis Model Mech 12). Using this model, we first investigated whether the anti-inflammatory effect of ginsenosides depends on their glycosidation pattern. For this purpose, the ginsenosides protopanaxadiol (PPD), F2, and Rb1 were used. PPD is not glycosidized, while F2 and Rb1 consist of the aglycone PPD with two glycone groups at the C-3 and C-20 positions of the steroid skeleton. In F2, these glycones are formed by the monosaccharide glucose, while in Rb1, they are formed by the disaccharide gentiobiose, in which two glucose molecules are linked by a β(1->6) bond. As a positive control, a synthetic version of the anti-inflammatory glucocorticoid drug beclomethasone (Bec) was used. The structures of these compounds are shown in Figure 1B.
[0200] The results showed that, as shown previously, Bec reduced neutrophil migration towards the wound site, while macrophage migration was unaffected. Ginsenosides PPD, F2 and Rb1 all similarly inhibited neutrophil migration (Fig. 1C and Fig. 2). As previously shown for ginsenoside Rg1, the effect of this ginsenoside was mediated by Gr, since the inhibition of neutrophil migration was abolished in a mutant line of zebrafish larvae lacking Gr function (Fig. 1C). Similar results were obtained when the expression of proinflammatory genes was used as a readout. Bec, PPD, F2 and Rb1 strongly suppressed the wound-induced increase in expression of il1b, il6 and mmp9 (Fig. 1D). Since the effect of ginsenosides did not seem to depend on the glycosidation pattern, we hypothesized that glycosidized ginsenosides are metabolized to the aglycone form. One class of enzymes that can catalyze the hydrolysis of the β-glycosidic bond between PPD and the glycone group are the β-glucosidases, of which two isoforms exist in vertebrates. Lysosomal acid β-glucosidase, also called glucocerebrosidase (GBA1), has been well studied because its deficiency leads to Gaucher disease, the most common lysosomal storage disorder in humans, characterized by the accumulation of glucosylceramide-containing tissue macrophages. In addition, there is a non-lysosomal glucosylceramidase (GBA2), which is structurally unrelated to GBA1, is located near the cell surface, and has different enzymatic characteristics, such as specificity for artificial substrates and inhibitors.
[0201] The role of Gba1 and Gba2 enzymes in the anti-inflammatory effects of ginsenosides was tested in zebrafish using the nonspecific chemical GBA inhibitor miglustat, and the specific GBA1 and GBA2 inhibitors ME656 and MZ31, respectively. In the presence of miglustat and MZ31, the reduction of neutrophil migration by F2 and Rb1 was abolished, whereas these inhibitors did not affect the action of PPD (Fig. 1E, G). However, treatment with ME656 did not alter the effect of any of the ginsenosides (Fig. 1F), indicating that this effect is Gba2 specific. To confirm the dependency of glycosidized ginsenosides on the Gba2 effect, a Gba2-deficient mutant line was used. In larvae of this line, F2 and Rb1 did not affect neutrophil migration, whereas PPD affected neutrophil migration (Fig. 1H). Taken together, these data suggest that the effects of glycosidic ginsenosides depend on GBA2, but not GBA1, hydrolyzing these compounds to their aglycone forms.
[0202] Example 4: Effect of glycosidized ginsenosides on side effects compared to traditional glucocorticoid drugs Other ginsenosides were also examined to determine whether similarly low levels of side effects and possible side effects depend on the glycosidation pattern of the ginsenosides. To this end, zebrafish embryos were treated with Bec, PPD, F2 and Rb1 and monitored for their effects on glucose and cortisol levels, larval length and tissue regeneration upon wounding, which can be considered a proxy for some well-known glucocorticoid side effects observed in the clinic. The anti-inflammatory glucocorticoid drug Bec was used as a positive control and indeed induced increased glucose levels (Figure 3A), decreased cortisol levels (Figure 3C), larval length (Figure 3E) and tissue regeneration (Figure 3F, G). The aglycone-type ginsenoside PPD did not affect glucose levels (Figure 3A), but reduced cortisol concentrations (Figure 3C), larval length (Figure 3E) and regeneration (Figure 3F, G). Interestingly, glycosidized ginsenosides F2 and Rb1 did not show any effect on glucose (Fig. 3A), nor did they affect cortisol concentration (Fig. 3C), larval length (Fig. 3E) or tissue regeneration (Fig. 3F, G). Upon wounding, glycosidized ginsenosides Rb1 and F2 showed a slight effect on cortisol and tissue regeneration, which was GBA2-dependent, as demonstrated using the chemical GBA2 inhibitor MZ31 (Fig. 3D, F, H), which may suggest that wounding increases the activity of Gba2, which then hydrolyzes Rb1 and F2.
[0203] The question that remains is why PPD has no effect on glucose levels, while all other measurements show similar (and in some cases smaller) effects than Bec. Since it is well known that the increase in glucose concentration induced by glucocorticoids depends exclusively on the transactivation activity of GR, we hypothesized that binding of PPD to Gr does not induce this transactivation activity. To test this hypothesis, we used a reporter fish line in which the GFP gene was fused to a GRE-containing promoter. Treatment of larvae of this line with Bec strongly increased the GFP signal throughout the larval body, whereas PPD (as well as F2 and Rb1) did not cause an increase in fluorescence intensity (Figure 3G,I). Furthermore, PPD did not increase the expression of well-known target genes of the transactivation activity of Gr, fkbp5, pck1 (which play an important role in the glucocorticoid-induced increase in cortisol concentration), and nfkbiaa (Figure 4B), confirming that PPD does not induce the transactivation activity of GR.
[0204] This indicates that the relatively minor side effects of PPD are abolished by glycosidation of the aglycone ginsenosides, since the transactivation activity of Gr is not induced. Together with the observed effects of ginsenosides on inflammatory responses, these results suggest that glycosidation of ginsenosides inactivates these compounds, which can be converted to the active aglycone form via hydrolysis by the enzyme GBA2, whose activity is specifically increased in inflamed tissues.
[0205] Example 5: GBA2 abundance and activity is locally increased at sites of inflammation To test whether GBA2 activity is increased in inflamed tissues, we wounded the caudal fin of zebrafish larvae and measured gba1 and gba2 mRNA concentrations, GBA1 and GBA2 protein levels, and GBA2 activity levels. Results showed that wounding increased gba2 mRNA levels (Figure 5A), Gba2 protein levels (Figures 5B and 6A), and Gba2 enzyme activity (Figures 5D and 6C) in zebrafish larvae. To examine whether this increase was restricted to inflamed tissues at the wound site, larvae were divided into anterior and posterior parts (the latter including the wound site). A wound-induced increase in GBA2 protein levels was observed only in the posterior part of the body, but not in the anterior part (Figures 5C and 6B). No effect of wounding was observed on gba1 mRNA (Figure 5A) and GBA1 protein levels (Figures 5B and 6A). These data indicate that GBA2 concentration and activity are specifically increased at the site of inflammation.
[0206] Example 6: Effect of glucuronidation of dexamethasone on anti-inflammatory activity and side effects Since glycosidation of ginsenoside PPD eliminated its side effects, we wondered whether conjugation of a glycone group to synthetic glucocorticoid drugs such as dexamethasone could lead to the development of novel glucocorticoid drugs with reduced side effects. A glucuronidated form of dexamethasone (i.e., dexamethasone with glucuronic acid conjugated to the C21 position) with a glucose group conjugated to the C21 position via a β-glycosidic bond (GDex) is commercially available. This compound has been developed as a drug against inflammatory bowel disease based on the hydrolysis of the compound by β-glucosidase derived from gut microbiota. First, we measured the anti-inflammatory effect of GDex using our zebrafish tail fin wound model. As a result, GDex inhibited neutrophil migration similar to Bec and Dex, but did not affect macrophage migration (Figure 7A). The inhibition of neutrophil migration by Bec, Dex, and GDex was absent in gr mutant larvae, indicating that the effects of these compounds were mediated by Gr. Furthermore, wound-induced increased expression of inflammatory genes il1b, il6, mmp9, and mmp13 was strongly reduced by GDex, an effect similar to that observed after Dex treatment (Figure 7C). To examine the possible side effects of GDex, we measured glucose and cortisol levels and larval length after treatment with Bec, Dex, and GDex. Dex increased glucose concentrations and reduced cortisol levels and larval length, similar to Bec, whereas GDex showed only a negligible decrease in cortisol levels (Figure 7D, E, F). Furthermore, GDex, like glycosidic ginsenosides, did not induce the transactivation activity of Gr, whereas Bec and Dex induced the transactivation activity of Gr, as shown using the GRE:GFP reporter Fischla line (Figure 7G) and the expression levels of Gr genes fkbp5, pck1, and nfkbiaa (Figure 7H). These data indicate that GDex acts similarly to glycosidic ginsenosides Rb1 and F2, implying that GDex is inactive outside the inflamed tissues but active at these inflammatory sites.
[0207] Example 7: Effect of glycosidation of prednisolone on anti-inflammatory activity and side effects To investigate whether a similar modification of the glucocorticoid drug prednisolone (Pdn) would result in the same reduction in side effects, we synthesized a glucosidized compound from prednisolone (GPdn) in which a glucose group was conjugated to the C-21 position of Pdn. Using a zebrafish caudal fin wound model, we showed that GPdn inhibited neutrophil migration (Figure 8A). Similar to GDex, GPdn did not increase glucose levels (whereas Bec, Dex and Pdn did (Figure 8B)) and only slightly decreased cortisol concentrations (whereas Bec, Dex and Pdn caused significantly greater decreases (Figure 8D)). Under wound conditions, GPdn caused a slight increase in glucose concentrations (although this effect was considerably smaller than that of Pdn (Figure 8C)) and a large decrease in cortisol concentrations (again, this effect was smaller than that of Pdn (Figure 8E)) compared to non-wounded larvae. These additive side effects observed after wounding were reduced by treatment with MZ31, suggesting that these effects depend on GBA2-mediated conversion of GPdns to Pdns at the wound site.
[0208] Interestingly, the inhibition of neutrophil migration by GDex and GPdn, unlike the effect of glycosidized ginsenosides, is independent of GBA2 activity, as shown with the GBA2 inhibitor MZ31 (Figure 8A). This suggests that, like PPD, the uncleaved form is capable of binding Gr and activating it sufficiently to reduce neutrophil migration. Thus, it can be established that the conjugation of a single monosaccharide is not sufficient to inactivate glucocorticoids, but rather that larger, bulkier modifications are required. We therefore synthesized a second glycosidized form of prednisolone, forming the disaccharide gentiobiose at the C-21 position. The structures of Pdn, GPdn, and this gentiobiosidized prednisolone (GbPdn) are shown in Figure 9A. Treatment of zebrafish larvae with GbPdn reduced neutrophil migration after tail fin wounding (Fig. 9B) and suppressed the expression of proinflammatory genes il1b, il6, and il8 (Fig. 9C), effects similar to those observed upon Pdn and GPdn treatment (Fig. 9B, C). The effect of GbPdn, but not GPdn, on neutrophil migration was abolished by MZ31, suggesting that GbPdn is an inactive molecule and requires removal of the bulky gentiobiose group via hydrolysis by GBA2.
[0209] Furthermore, GbPdn did not affect glucose or cortisol concentrations (Fig. 9B,D), nor did it affect larval length (Fig. 10A). A slight effect was observed on caudal fin regeneration. This effect was significantly smaller than Pdn and was dependent on Gba2 activity, as shown with MZ31 (Fig. 10D). Under wounding conditions, both GPdn and GbPdn induced elevated glucose levels (Fig. 9B) and reduced cortisol concentrations (Fig. 9D), likely as a result of elevated GBA2 activity. Using a GRE:GFP reporter zebrafish line, we showed that neither GPdn nor GbPdn induced the transactivation activity of Gr (Fig. 10E,G), and examination of the expression of Gr target genes fkbp5, pck1 and nfkbiaa confirmed this lack of effect (Fig. 10H). Apparently, monosaccharide conjugation abolishes the ability of Pdn to induce the transactivation activity of Gr and is sufficient to abolish almost all glucocorticoid side effects in this model.
[0210] To prove whether the lack of GBA2 activity outside inflamed tissues is responsible for the lack of side effects of glycosidated glucocorticoids, we overexpressed GBA2 by injecting a plasmid containing gba2 cDNA driven by a constitutively active CMV promoter into zebrafish larvae. Overexpression was confirmed by qPCR analysis, which showed a dramatic increase in gba2 mRNA concentration (Figure 10B). When Gba2 was overexpressed systemically, Pdn, GPdn and GbPdn showed similar detrimental effects on glucose and cortisol concentrations, and transactivation. The latter effect was demonstrated by using a GRE:GFP reporter line (Figure 10F, G) and by examining the expression of Gr target genes fkbp5, pck1 and nfkbiaa (Figure 10I). These data indicate that due to the absence of GBAa2 activity in most of the body, glycosidated glucocorticoids remain in an inactive glycosidated state that does no harm to the body.
[0211] Example 8: Examination of GR activation in human cells in vitro The in vitro binding of Dex, Pdn, GPdn and GbPdn to human GR was examined using a competitive ligand binding assay. The results showed that Bec and Pdn had similar binding affinities (IC50 of about 4.8 and about 12 nM, respectively). The affinity of Pdn was slightly lower (IC50 about 350 nM), whereas that of GbPdn was dramatically lower (IC50 about 17 mM) (Figure 11A). Apparently, glucosylation of Pdn reduces the binding affinity of the ligand by about 30-fold, while gentiobiosylation reduces the affinity by about 1400-fold. Using HeLa cell culture medium, the translocation of GR to the nucleus after administration of Pdn, GPdn and GbPdn was measured. It was observed that the nuclear translocation was maximal after treatment with Pdn and GPdn, while GbPdn only slightly increased the translocation level compared to vehicle treatment (Figures 11B, 12A). These data indicate that gentiobiosylation is preferred over glucosylation when designing prodrugs, since disaccharide conjugation leads to a greater degree of steroid inactivation.Interestingly, co-treatment with the proinflammatory cytokine TNF-α induced complete translocation of GbPdn, similar to Pdn and GPdn, and this effect was abolished by MZ31 treatment and therefore dependent on GBA2 activity (Figure S11B).
[0212] To study the anti-inflammatory effects of GPdn and GbPdn in human cells, HeLa cells were treated with TNF-α. This treatment induced the expression of the proinflammatory genes IL1B (Fig. 11C), IL8 (Fig. 11D), and MMP13 (Fig. 12B), all three of which were strongly repressed by Pdn. GPdn and GbPdn similarly suppressed the TNF-α-induced increase in the expression of these genes. In GbPdn, the suppression of IL1B and IL8 was dependent on the activity of GBA2, as its effect was reduced by MZ31 treatment. These results are consistent with the GBA2-dependence of the anti-inflammatory effect of GbPdn observed in zebrafish.
[0213] To examine the transactivation activity of GR in HeLa cells, we measured the expression levels of GR target genes FKBP5, NFKBIA, GILZ, and SGK1. Pdn strongly increased the expression of these genes, whereas GPdn and GbPdn did not or only slightly increased the expression levels of these genes (Fig. 11E, F, 12C, D). TNF-α treatment barely changed the expression of these genes in GPdn-treated cells, but increased the expression of these genes in GbPdn-treated cells, an effect that was Gba2-dependent and strongly reduced by MZ31 (Fig. 11E, F, 12C, D). This role of GBA2 was confirmed in experiments using lentivirus-mediated shRNA knockdown of GBA1 or GBA2. Knockdown of GBA2, but not GBA1, suppressed the increased expression of FKBP5 and NFKBIA induced by TNF-α (Fig. 11G, 12E). Finally, we overexpressed GBA2 in HeLa cells by transfection with a plasmid containing the CMV:GBA2 DNA construct. In these GBA2-overexpressing cells, Pdn, GPdn and GbPdn similarly increased the expression levels of FKBP5 and NFKBIA. These data indicate that TNF-α increases the activity of GBA2 and gene transactivation following treatment with GbPdn, but has a very modest effect following GPdn treatment.
[0214] Example 9: Collagen antibody-induced arthritis (CAIA) mouse experiment To examine the effect of GbPdn in a mammalian model of inflammatory disease, we performed an induced arthritis assay as described in the "Assay" section above. Using a collagen antibody-induced arthritis (CAIA) model in mice, arthritis was induced by injecting a cocktail of antibodies against collagen on day 1 and LPS on day 4 (Figure 13). Mice were then treated daily with vehicle, Pdn (12.5 mg / kg or 25 mg / kg) or GbPdn (12.5 mg / kg, 25 mg / kg or 50 mg / kg). Arthritis scores were measured daily from day 5 to day 15. Vehicle-treated mice reached high arthritis scores (approximately 15) and these levels remained stable until day 14 (Figure 14A). In contrast, in Pdn- and GbPdn-treated mouse groups, scores declined rapidly after treatment initiation. The Pdn-treated group showed the greatest reduction (score approximately 0) on day 11 of the experiment, whereas the GbPdn 12.5 mg / kg, 25 mg / kg, and 50 mg / kg-treated groups showed the greatest effect on days 15, 14, and 13, respectively (Fig. 14A).
[0215] As a second indicator of the inflammatory response in these animals, serum IL-6 concentrations were measured on days 10 and 15. The results of this experiment showed a significant decrease in IL-6 levels in all treatment groups compared to the vehicle group, but the 12.5 mg / kg GbPdn treatment group had slightly higher IL-6 concentrations compared to the other groups treated with Pdn or GbPdn (Figure 14B). On day 15, IL-6 concentrations were not detected in the serum of all groups treated with Pdn or GbPdn (except for very low concentrations detected in two (out of four) mice in the 12.5 mg / kg GbPdn group). Taken together, these data indicate that GbPdn is a highly effective anti-inflammatory drug that shows only a delayed activity compared to Pdn.
[0216] To investigate whether GbPdn induces side effects in arthritic mice, we examined the effect of treatment on serum insulin and corticosterone levels (days 14 and 15, respectively), which are biomarkers of glucocorticoid side effects. The data demonstrated that Pdn treatment significantly increased insulin levels, whereas GbPdn treatment did not alter insulin concentrations (Figure 14C). In addition, Pdn strongly suppressed corticosterone levels, whereas GbPdn did not affect corticosterone levels (Figure 14D). These data are consistent with the assumption that the compound is activated only at the site of inflammation, and indicate that GbPdn does not induce any side effects in this animal model.
[0217] Finally, the mRNA levels (using qPCR) of several GR target genes were examined in liver and muscle tissues, and in hind ankle joint tissues. The data showed that Pdn treatment increased the mRNA levels of Fkbp5, Pck1, and Gilz in liver tissue (Figure 14E), Redde1, Foxo3, and Klf15 in muscle tissue (Figure 14F), and Gilz and Fkbp5 in joints (Figure 14G). Interestingly, GbPdn treatment did not affect the expression of GR target genes examined in liver or muscle tissues. However, Gilz and Fkbp5 mRNA levels in joints were increased in the GbPdn-treated group, suggesting that inflammation in this tissue caused the local conversion of GbPdn to Pdn and subsequent activation of GR.
[0218] Example 10: Confirmation of Gentiobiose Cleavage by Mass Spectrometry To investigate whether GbPdn is converted to Pdn by Gba2 in a single step or whether the two glucose groups are cleaved independently, we performed a cleavage confirmation assay by liquid chromatography / mass spectrometry as described in the "Assay" section above. After treatment with 25 μM GbPdn for 6 h (2 h before wounding and 4 h after wounding), we measured the concentration levels of GbPdn, Pdn, and a possible intermediate metabolite, glucose-prednisolone (GPdn), in wounded and non-wounded zebrafish larvae. This experiment was performed in wild-type zebrafish in the presence or absence of MZ31 and in larvae of the gba2- / - line. The results of this experiment showed that GbPdn was mainly converted to Pdn, which was observed only in wounded larvae (Figure 15A). Interestingly, the high conversion rate of GBPdn to Pdn in wounded larvae was almost abolished in the presence of MZ31 (Fig. S15A) and was not observed in wounded gba2- / - larvae (Fig. S15B). These results indicate that this conversion is dependent on inflammation-induced Gba2 activity. Notably, very low concentrations of GPdn were detected in all treatment groups (Fig. S15A,B), indicating that GbPdn is hardly converted to GPdn, but that Gba2 removes all gentiobiose groups from GbPdn in a single step.
Claims
1. Formula I: [Formula 1] [In the formula: A is selected from monosaccharides and disaccharides; and B is selected from an anti-inflammatory moiety or a chemotherapeutic moiety. or a pharma- ceutically acceptable salt, stereoisomer, acid or solvate thereof.
2. 2. The compound of claim 1, wherein A is selected from glucose, galactose, mannose, fructose and any acid form thereof, and any disaccharide formed from one or two of glucose, galactose, mannose, fructose and any acid form thereof.
3. 3. The compound of claim 1 or claim 2, wherein A is a disaccharide formed from one or two of glucose, galactose, mannose, fructose and the acid form of any of them; optionally, the disaccharide is gentiobiose.
4. 3. The compound of claim 1 or claim 2, wherein A is a disaccharide formed from two aldohexoses; optionally, A is a disaccharide formed from one or two glucose, galactose, idose, altrose, and the acid form of any of them.
5. 3. The compound of claim 1 of claim 2, wherein A is a monosaccharide selected from glucose, galactose, mannose, fructose and any acid form thereof; optionally, the monosaccharide is glucose or glucuronic acid.
6. 2. The compound of claim 1, wherein B is an anti-inflammatory moiety.
7. 7. The compound of claim 6, wherein the anti-inflammatory moiety is or includes a corticosteroid (e.g., a glucocorticoid), a nonsteroidal glucocorticoid receptor agonist, a nonsteroidal anti-inflammatory, disease-modifying antirheumatic drug, or a rapamycin.
8. 2. A compound according to any one of the preceding claims, wherein B is or comprises a corticosteroid (e.g. a glucocorticoid) selected from hydrocortisone-type corticosteroids, triamcinolone acetonide-type corticosteroids, methasone-type corticosteroids, betamethasone dipropionate-type corticosteroids and methylprednisolone aceponate-type corticosteroids.
9. B: alclometasone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, ciclometasone, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, cortifen, cortisol (hydrocortisone), cortisone, cortivazol, cortodoxone, deflazacort , desonide, desoximetasone, dexamethasone, dichlorisone, diflucortolone, diflorasone, difluprednate, formocortal, fluazacort, flucloronide, fludrocortisone, flucortin, flucortolone, flumethasone, flunisolide, fluocinolone, fluocinolone acetonide acetonide, fluocinonide, fluocortin, fluorometholone, fluperolone, fluprednidene, fluprednisolone, flurandrenolide, fluticasone, halcinonide, halobetasol, halometasone, hydrocortamate, icometasone, isoflurane, lotoprednol, mazipredone, medrysone, mepred 2. A compound according to any one of the preceding claims which is or comprises the molecular radical of nisone, methylprednisolone, mometasone, nicocortonide, paramethasone, prednicarbate, prednisolone, prednimustine, prednisone, procinonide, tixocortol, triamcinolone or triamcinolone acetonide, or an ester of any of them.
10. The compounds are esters thereof, and optionally the esters are selected from the group consisting of acetate, adamantoate, benzoate, benzofurancarboxylate, benzoyl-β-aminoisobutyrate, butyrate, caproate, carboxylate, chlorambucil, chlorphenacyl, cipecilate, cyclopentanepropionate, cyclopentylpropionate, cyclopropylcarboxylate, cypionate, dicibate, dichloroacetate, diethylaminoacetate, enanthanate ...cypecilate, cyclopentanepropionate, cyclopropylcarboxylate, cypionate, dicibate, dichloroacetate, diethylaminoacetate, enanthanate, benzoyl-β-aminoisobutyrate, butyrate, caproate, carboxylate, chlorambucil, chlorphenacyl, cypecilate, cyclopentanepropionate, cyclopropylcarboxylate, cypionate, dicibate, dichloroacetate, diethylaminoacetate, enanthanate, benzoyl-β-aminoisobutyrate, 10. The compound of claim 9, comprising a group selected from the group consisting of acetate, embutate, etabonate (ethyl carbonate), fuorate, hemisuccinate, hexanoate, isobutyrate, isonicotinate, linoleate, metasulfobenzoate, metembonate, palmitate, phosphate, piperidinoacetate, pivalate, propionate, salicylate, stearoyl glycolate, succinate, suleptanate, sulfate, tert-butyl acetate, tetrahydrophthalate, troxundate, valerate, or xanthogenate.
11. 2. The compound of any one of the preceding claims, wherein B is a chemotherapeutic moiety.
12. Formula II: [Case 2] [In the formula: R 1 is selected from a monosaccharide or a disaccharide; R 2 is H, substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Alkoxy, substituted or unsubstituted C 3 -C 8 alkenyl, R 3 and R 4 are independently H, OH, C 1 -C 4 Substituted or unsubstituted alkyl, OR 9 , O.C.(O)R 9 or R 3 and R 4 together with the carbon atom to which they are attached form a substituted or unsubstituted 5- or 6-membered heterocycloalkyl; R 5 , R 6 , R 7 and R 8 each independently represents H, OH, halo, substituted or unsubstituted -C 1 -C 4 Alkyl or OR 10 Selected from; R 9 is H or -C 1 -C 8 Selected from substituted or unsubstituted alkyl; R 10 is H or -C 1 -C 8 Selected from substituted or unsubstituted alkyl; X is selected from =O or -OH. or a pharma- ceutically acceptable salt, stereoisomer, acid or solvate thereof.
13. R 1 is selected from glucose, galactose, mannose, fructose and any acid form thereof, and any disaccharide formed from one or two of glucose, galactose, mannose, fructose and any acid form thereof.
14. R 1 14. The compound according to claim 12 or 13, wherein is a disaccharide formed from one or two of glucose, galactose, mannose, fructose and the acid form of any of them.
15. R 1is a disaccharide formed from two aldohexoses and the acid form of either of them, and optionally R 1 14. The compound according to claim 12 or 13, wherein is a disaccharide formed from one or two glucose, galactose, idose and altrose.
16. R 1 The compound according to any one of claims 12 to 15, wherein is gentiobiose.
17. R 1 is a monosaccharide selected from glucose, galactose, mannose, fructose and the acid form of any of them; optionally, the monosaccharide is glucose or glucuronic acid.
18. R 2 is H and substituted or unsubstituted C 1 -C 8 alkyl; optionally, where R 2 The compound according to any one of claims 12 to 17, wherein is H.
19. R 3 H, OH and OC(O)R 9 The compound according to any one of claims 12 to 18, selected from:
20. R 9 but substituted or unsubstituted -C 1 -C 8 alkyl; optionally, R 8 But unsubstituted -C 1 -C 8 20. The compound of any one of claims 12 to 19, which is alkyl.
21. R 4 is H, OH, or C 1 -C 4 alkyl; optionally, R 4 The compound according to any one of claims 12 to 20, wherein is selected from H, OH, or methyl.
22. R 3 and R 4 and together with the carbon atom to which they are attached form a substituted or unsubstituted 5- or 6-membered heterocycloalkyl.
23. R 3 and R 4 together with the carbon atom to which they are attached form a substituted or unsubstituted 1,3 dioxolane.
24. 1,3 dioxolane is -C 1 -C 4 24. The compound of claim 23, wherein the 2-position is substituted with one or two groups selected from alkyl (e.g., methyl), 5- or 6-membered cycloalkyl, or 5- or 6-membered heterocycle (e.g., furan).
25. R 2 is H and R 3 is OH, and R 4 The compound according to any one of claims 12 to 17, wherein is H.
26. R 2 is H and R 3 and R 4 together with the carbon atom to which they are attached form a substituted or unsubstituted 1,3 dioxolane.
27. R 2 is H and R 4 C 1 -C 4 alkyl; optionally, R 2 is H and R 4 The compound according to any one of claims 12 to 17, wherein is methyl.
28. R 2 is H and R 3 OC(O)R 9 and R 4is H; optionally, R 9 is substituted or unsubstituted -C 1 -C 8 The compound according to any one of claims 12 to 17, which is alkyl.
29. R 10 The compound according to any one of claims 12 to 28, wherein is H.
30. R 5 is selected from H and halo; optionally, R 5 30. The compound according to any one of claims 12 to 29, wherein is selected from H, F and Cl.
31. R 8 is selected from H and halo; optionally, R 8 The compound according to any one of claims 12 to 30, wherein is selected from H, F and Cl.
32. R 6 and R 7 The compound of any one of claims 12 to 31, wherein each is H.
33. 33. The compound of any one of claims 12 to 32, wherein X is OH.
34. 33. The compound of any one of claims 12 to 32, wherein X is O.
35. Formula (Vb): [C3] [In the formula: R 1 is selected from mono- or disaccharides and the acid form of either; R 2 is H, substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Alkoxy, substituted or unsubstituted C 3 -C 8 alkenyl; R 3 and R 4 are independently H, OH, C 1 -C 4 Substituted or unsubstituted alkyl, OR 9 , O.C.(O)R 9 or R 3 and R 4 together with the carbon atom to which they are attached form a substituted or unsubstituted 5- or 6-membered heterocycloalkyl; R 5 , R 6 , R 7 and R 8 each independently represents H, OH, halo, substituted or unsubstituted -C 1 -C 4 Alkyl, or OR 10 Selected from; R 9 is H or -C 1 -C 8 substituted or unsubstituted alkyl; and R 10 is H or -C 1 -C 8 substituted or unsubstituted alkyl; or a pharma- ceutically acceptable salt, stereoisomer, acid or solvate thereof.
36. R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 36. The compound of claim 35, wherein any one or more of:
37. R 1 is a disaccharide formed from two aldohexoses and their acid forms, and R 2 is H and R 3 is OH, and R 4 is H; optionally, R 6is H and R 7 is H and R 8 is H, and R 9 The compound of claim 35, wherein is H.
38. R 1 is a disaccharide formed from one or two of D-glucose, D-galactose, L-idose, L-altrose, and the acid form of any of them; optionally, R 1 is gentiobiose.
39. 2. The compound according to any one of the preceding claims, wherein the compound is a substrate for glucosylceramidase beta 2 (GBA2).
40.
4. or a pharma- ceutically acceptable salt, stereoisomer, acid or solvate thereof.
41. Compound: [C5] or a pharma- ceutically acceptable salt, stereoisomer, acid, or solvate thereof.
42. A pharmaceutical composition comprising a compound according to any one of the preceding claims.
43. 43. The composition of claim 42, formulated for parenteral administration, optionally formulated for parenteral administration, and further optionally formulated for injection.
44. A compound according to any one of claims 1 to 41, or a pharmaceutical composition according to claim 42 or 43, for use as a medicament.
45. A compound according to any one of claims 1 to 42 or a pharmaceutical composition according to claim 42 or 43 for use in the treatment of inflammation.
46. A compound according to any one of claims 1 to 41 or a pharmaceutical composition according to claim 42 or 43 for use in the treatment of an inflammatory condition or other condition characterised by hyperactivity of the immune system.
47. 47. The compound or composition for use according to claim 46, wherein the inflammatory or other condition is selected from arthropathy, osteoarthropathy, gout, rheumatoid arthritis, other autoimmune disorders (e.g. systemic lupus erythematosus (SLE), inflammatory bowel disease (including IBD, Crohn's disease, ulcerative colitis), multiple sclerosis, chronic inflammatory demyelinating polyneuropathy (CIPD)), infectious diseases (e.g. COVID-19 and tuberculosis), asthma, chronic obstructive pulmonary disease (COPD), allergic and non-allergic rhinitis and sinusitis, tendonitis, nasal polyps, skin conditions (e.g. rash, dermatitis, pruritus, eczema, dermatomycoses, lichen sclerosus or rubra, and psoriasis), eye diseases (e.g. uveitis, conjunctivitis, macular edema), otitis, thyroiditis, sarcoidosis, myositis, vasculitis, hemorrhoids, organ rejection in transplant recipients and graft versus host disease.
48. 48. The compound or composition for use according to claim 46 or 47, wherein the inflammatory or other condition is selected from rheumatoid arthritis, other autoimmune disorders (e.g. systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD)) and thyroiditis.
49. A compound according to any one of claims 1 to 41 or a pharmaceutical composition according to claim 42 or 43, for use in the treatment of a condition characterised by hyperproliferation of cells belonging to the immune system, optionally said condition being selected from acute lymphoblastic leukemia (ALL), or acute myeloid leukemia (AML).
50. A compound according to any one of claims 1 to 41, or a pharmaceutical composition according to claim 42 or 43, for use in the treatment of cancer.
51. 51. The compound or composition for use according to any one of claims 44 to 50, wherein said use comprises parenteral administration of said compound or composition to a patient, optionally said administration comprises parenteral administration, and further optionally said administration comprises injection.
52. Use of a compound according to any one of claims 1 to 41 as an anti-inflammatory agent, comprising contacting the compound (optionally in vitro) with a cell expressing glucosylceramidase beta 2 (GBA2).
53. 53. The use according to claim 52, wherein the cell is a cell of a tissue or organ.
54. 54. The use according to claim 53, wherein the cells are cells in cell culture.
